[go: up one dir, main page]

WO2025171300A1 - Lipides et nanoparticules lipidiques les comprenant - Google Patents

Lipides et nanoparticules lipidiques les comprenant

Info

Publication number
WO2025171300A1
WO2025171300A1 PCT/US2025/015066 US2025015066W WO2025171300A1 WO 2025171300 A1 WO2025171300 A1 WO 2025171300A1 US 2025015066 W US2025015066 W US 2025015066W WO 2025171300 A1 WO2025171300 A1 WO 2025171300A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkenyl
antigenic polypeptide
independently
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/015066
Other languages
English (en)
Inventor
Ying Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Therapeutics Inc
Original Assignee
General Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Therapeutics Inc filed Critical General Therapeutics Inc
Publication of WO2025171300A1 publication Critical patent/WO2025171300A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Definitions

  • nucleic acids are currently being developed as therapeutics for the prevention or treatment of a number of diseases.
  • active agents such as diagnostic agents, small molecule drugs, proteins, and nucleic acids
  • nucleic acids represents a continuing medical challenge.
  • the delivery of nucleic acids to cells is made difficult by the relative instability and low cell permeability of such species.
  • Lipid-containing nanoparticle compositions, liposomes, and lipoplexes have proven effective as transport vehicles for active agents into cells and/or intracellular compartments. Though a variety of such lipid-containing nanoparticle compositions have been demonstrated, improvements in safety, efficacy, and specificity are still lacking.
  • lipids including lipids that exhibit high efficacy and high safety to facilitate the delivery of therapeutic, diagnostics, and/or prophylactics such as nucleic acids to cells.
  • compositions including a compound described herein and an active agent.
  • present disclosure also provides methods of using the compositions for delivering an active agent to a subject.
  • lipid compounds defined by Formula I: or a pharmaceutically acceptable salt thereof, wherein: A, M, R 1 , G, x and y are as defined herein.
  • Formula II or a pharmaceutically acceptable salt thereof, wherein: A, M, R 1 , R 2 , G, m, n, x and y are as defined herein.
  • Formula III or a pharmaceutically acceptable salt thereof, wherein: A, M, R 1 , G, m, x and y are as defined herein.
  • Described herein are compounds of Formula V : or a pharmaceutically acceptable salt thereof, wherein A, M, E, G, R 1 , R 3 , R 4 , m, x, y, and z are as defined herein.
  • compounds of Formula VI or a pharmaceutically acceptable salt thereof, wherein A, M, G, R 1 , R 5 , m, x, y, and z are as defined herein. In some embodiments, wherein
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl.
  • i, j, k, p, q, and r are independently 0, 1, 2, 3 or 4.
  • m, n, x, y, and z are independently an integer from 1 to 15.
  • R 1 and R 2 are independently for each occurrence linear or cyclic alkyl, alkenyl, or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons.
  • R 4 is absent or -S-S-.
  • R 5 is -S-S-.
  • L is selected from pharmaceutically acceptable salt thereof.
  • compositions comprising a compound of formula I, II, III, IV, V, VI, or any combination thereof.
  • provided herein are methods for the delivery of agents (e.g., polynucleotides).
  • agents e.g., polynucleotides.
  • Fig. 1 illustrates representative synthesis routes for GTX018, GTX187, and GTX188.
  • Fig. 2 illustrates representative synthesis route for ionizable lipids GTX215 and GTX216.
  • Fig. 3 illustrates representative synthesis route for biodegradable ionizable lipids with S-S bond, GTX025 and GTX225.
  • Fig. 4 illustrates representative synthesis route for ionizable lipids GTX046 and GTX047, with anti-oxidant 7-dehydrocholesterol (7-DHC) tail.
  • Fig. 5 illustrates representative synthesis route for ionizable lipid GTX019.
  • Fig. 6 illustrates representative synthesis route for ionizable lipids GTX325, GTX345, and GTX355.
  • Fig. 7 illustrates representative synthesis route for ionizable lipid GTX045.
  • Fig. 8A-8H shows 1 H NMR spectra for ionizable lipids.
  • (8A) 1 H NMR spectra for GTX187,
  • (8B) 1 H NMR spectra for GTX087,
  • (8D) 1 H NMR spectra for GTX018
  • (8E) NMR spectra for GTX215,
  • (8F) H NMR spectra for GTX047 8G) ‘H NMR spectra for GTX046 (8H) ‘ H NMR spectra for GTXO 19.
  • Fig. 9 shows fluorescent and bright field images of cells transfected with EGFP mRNA- LNP at 500 ng in 24-well plate for 24 hours.
  • LNPs were formulated using GTX187 or SM-102.
  • Fig. 10 shows whole animal IVIS imaging of mice injected with Luciferase mRNA- LNP after 6 hours injection of 1 ug mRNA (I.M. injection).
  • LNPs were formulated using SM- 102, GTX 187 and GTX 188.
  • Fig. 11A-1 ID shows evaluation of influenza mRNA-LNP vaccine targeting PR8 virus strain.
  • (11A) illustrates mouse study as scheduled including 2 immunizations on day 0 and day 14, blood draw on day 27, and virus challenge on day 28.
  • (1 IB) shows a graph of neutralizing antibody titer of indicated vaccine groups.
  • (11C) shows a graph of IgG titer of indicated vaccine groups.
  • (1 ID) shows a graph of mouse body weight loss after virus challenge (20% of body weight loss consider death).
  • Fig. 12 shows whole animal IVIS imaging of mice injected with Luciferase mRNA- LNP after 6 hours injection of 1 ug mRNA (I.M. injection).
  • LNPs were formulated using GTX 187, GTX 189, and SM-102.
  • Fig. 13 shows whole animal IVIS imaging of mice injected with Luciferase mRNA- LNP after 6 hours injection of 1 ug mRNA (I.M. injection). LNPs were formulated using GTX045 and SM-102.
  • Fig. 14 shows animal IVIS imaging of mice injected with Luciferase mRNA-LNP after 6 hours injection of 1 ug mRNA (I.M. injection). LNPs were formulated using C1A5.
  • Fig. 15 shows whole animal IVIS imaging of mice injected with Luciferase mRNA- LNP after 6 hours injection of 1 ug mRNA (I.M. injection). LNPs were formulated using F1F5.
  • Fig. 16 shows whole animal IVIS imaging of mice injected with Luciferase mRNA- LNP after 6 hours injection of 1 ug mRNA (I.M. injection).
  • LNPs were formulated using GTX355
  • compositions including a compound of the invention and an agent.
  • present disclosure also provides methods using the compositions for delivering an agent to a subject. These nanomaterials are used in applications such as gene therapy and drug delivery.
  • the terms “comprise” (as well as forms, derivatives, or variations thereof, such as “comprising” and “comprises”) and “include” (as well as forms, derivatives, or variations thereof, such as “including” and “includes”) are inclusive (i.e., open-ended) and do not exclude additional elements or steps.
  • the terms “comprise” and/or “comprising,” when used in this specification specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
  • Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. By “about” is meant within 5% of the value, e.g., within 4, 3, 2, or 1% of the value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself.
  • a range may be construed to include the start and the end of the range.
  • a range of 10% to 20% i.e., range of 10%-20%) can includes 10% and also includes 20%, and includes percentages in between 10% and 20%, unless explicitly stated otherwise herein.
  • inflammation refers to a biologic response involving an upregulation of the immune system, which may include an increase in protein activity related to inflammation or an immune response (e.g., pro-inflammatory markers such as chemokines and cytokines) and symptoms of inflammation (e.g., pain, heat, redness and/or edema). Inflammation is acute or chronic.
  • pro-inflammatory markers such as chemokines and cytokines
  • symptoms of inflammation e.g., pain, heat, redness and/or edema.
  • anti-inflammatory agent includes agents that elicit a biological or medical response in a subject that reduce inflammation (either acute or chronic) or downregulate the immune response, for example, by reducing or inhibiting enzyme or protein activity related to inflammation or an immune response; by ameliorating one or more symptoms of inflammation or an immune response; or by slowing or delaying of the inflammatory process or the immune response.
  • the terms “may,” “optionally,” and “may optionally” are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur.
  • the statement that a formulation "may include an excipient” is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.
  • administering to a subject includes any route of introducing or delivering to a subject an agent. Administration can be carried out by any suitable route, including oral, topical, transcutaneous, transdermal, intra-joint, intra-arteriole, intradermal, intraventricular, intralesional, intranasal, rectal, vaginal, by inhalation, via an implanted reservoir, parenteral (e.g., subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques), and the like.
  • parenteral e.g., subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injections or infusion techniques
  • Constant administration means that the compounds are administered at the same point in time or essentially immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.
  • Systemic administration refers to the introducing or delivering to a subject an agent via a route which introduces or delivers the agent to extensive areas of the subject's body (e.g. greater than 50% of the body), for example through entrance into the circulatory or lymph systems.
  • local administration refers to the introducing or delivery to a subject an agent via a route which introduces or delivers the agent to the area or area immediately adjacent to the point of administration and does not introduce the agent systemically in a therapeutically significant amount.
  • locally administered agents are easily detectable in the local vicinity of the point of administration but are undetectable or detectable at negligible amounts in distal parts of the subject's body.
  • Administration includes self-administration and the administration by another.
  • beneficial agent and “active agent” are used interchangeably herein to refer to a chemical compound or composition that has a beneficial biological effect.
  • beneficial biological effects include both therapeutic effects, i.e., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, i.e., prevention of a disorder or other undesirable physiological condition.
  • the terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, isomers, fragments, analogs, and the like.
  • “Therapeutic agent” refers to any composition that has a beneficial biological effect.
  • Beneficial biological effects include both therapeutic effects, e.g., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, e.g., prevention of a disorder or other undesirable physiological condition.
  • the terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, proagents, active metabolites, isomers, fragments, analogs, and the like.
  • therapeutic agent when used, or when a particular agent is specifically identified, it is to be understood that the term includes the agent per se as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, proagents, conjugates, active metabolites, isomers, fragments, analogs, etc.
  • “Inhibit,” “inhibiting,” and “inhibition” mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
  • “Inactivate”, “inactivating” and “inactivation” means to decrease or eliminate an activity, response, condition, disease, or other biological parameter due to a chemical (covalent bond formation) between the ligand and a its biological target.
  • reduce or other forms of the word, such as “reducing” or “reduction,” is meant lowering of an event or characteristic (e.g., tumor growth). It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reduces tumor growth” means reducing the rate of growth of a tumor relative to a standard or a control.
  • treating or “treatment” of a subject includes the administration of a drug to a subject with the purpose of preventing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of a disease or disorder.
  • the terms “treating” and “treatment” can also refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage.
  • prevent or other forms of the word, such as “preventing” or “prevention,” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed.
  • the terms “prevent” or “suppress” can refer to a treatment that forestalls or slows the onset of a disease or condition or reduced the severity of the disease or condition.
  • a treatment can treat a disease in a subject having symptoms of the disease, it can also prevent or suppress that disease in a subject who has yet to suffer some or all of the symptoms.
  • the term “preventing” a disorder or unwanted physiological event in a subject refers specifically to the prevention of the occurrence of symptoms and/or their underlying cause, wherein the subject may or may not exhibit heightened susceptibility to the disorder or event.
  • effective amount” of a therapeutic agent is meant a nontoxic but sufficient amount of a beneficial agent to provide the desired effect.
  • an “effective amount” of a beneficial can also refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.
  • an “effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • a “therapeutically effective amount” of a therapeutic agent refers to an amount that is effective to achieve a desired therapeutic result
  • a “prophylactically effective amount” of a therapeutic agent refers to an amount that is effective to prevent an unwanted physiological condition.
  • Therapeutically effective and prophylactically effective amounts of a given therapeutic agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the subject.
  • the term “therapeutically effective amount” can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect.
  • the precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the drug and/or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.
  • the term “pharmaceutically acceptable” component can refer to a component that is not biologically or otherwise undesirable, i.e., the component may be incorporated into a pharmaceutical formulation of the invention and administered to a subject as described herein without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained.
  • pharmaceutically acceptable refers to an excipient, it is generally implied that the component has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
  • “Pharmaceutically acceptable carrier” (sometimes referred to as a “carrier”) means a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic and includes a carrier that is acceptable for veterinary and/or human pharmaceutical or therapeutic use.
  • carrier or “pharmaceutically acceptable carrier” can include, but are not limited to, phosphate buffered saline solution, water, emulsions (such as an oil/water or water/oil emulsion) and/or various types of wetting agents.
  • carrier encompasses, but is not limited to, any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations and as described further herein.
  • “pharmaceutically acceptable salt” is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, nontoxic, acid or base addition salts thereof.
  • the salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • salts of the present compounds further include solvates of the compounds and of the compound salts.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxy maleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, H00C-(CH2)n- COOH where n is 0-4, and the like, or using a different acid that produces the same counterion.
  • Lists of additional suitable salts may be found, e.g.,
  • the term “pharmacologically active” can refer to a derivative or analog (e.g., a salt, ester, amide, conjugate, metabolite, isomer, fragment, etc.) having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
  • control is an alternative subject or sample used in an experiment for comparison purposes.
  • a control can be "positive” or “negative.”
  • a “subject” is meant an individual.
  • the “subject” can include domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, goats, sheep, pigs, dogs, cats, etc.), and birds (e.g., chickens, turkeys, songbirds, etc.).
  • “Subject” can also include a mammal, such as a primate or a human.
  • the subject can be a human or veterinary patient.
  • the term “patient” refers to a subject under the treatment of a clinician, e.g., physician. Administration of the therapeutic agents can be carried out at dosages and for periods of time effective for treatment of a subject.
  • the subject is a human.
  • nucleic acid as used herein means a polymer composed of nucleotides, e.g. deoxyribonucleotides or ribonucleotides.
  • ribonucleic acid and “RNA” as used herein mean a polymer composed of ribonucleotides.
  • deoxyribonucleic acid and “DNA” as used herein mean a polymer composed of deoxyribonucleo tides.
  • oligonucleotide denotes single- or double-stranded nucleotide multimers of from about 2 to up to about 100 nucleotides in length.
  • Suitable oligonucleotides may be prepared by the phosphoramidite method described by Beaucage and Carruthers, Tetrahedron Lett., 22:1859-1862 (1981), or by the triester method according to Matteucci, et al., J. Am. Chem. Soc., 103:3185 (1981), both incorporated herein by reference, or by other chemical methods using either a commercial automated oligonucleotide synthesizer or VLSIPSTM technology.
  • double-stranded When oligonucleotides are referred to as “double-stranded,” it is understood by those of skill in the art that a pair of oligonucleotides exist in a hydrogen-bonded, helical array typically associated with, for example, DNA.
  • double- stranded As used herein is also meant to refer to those forms which include such structural features as bulges and loops, described more fully in such biochemistry texts as Stryer, Biochemistry, Third Ed., (1988), incorporated herein by reference for all purposes.
  • polynucleotide refers to a single or double stranded polymer composed of nucleotide monomers. In some embodiments, the polynucleotide is composed of nucleotide monomers of generally greater than 100 nucleotides in length and up to about 8,000 or more nucleotides in length.
  • polypeptide refers to a compound made up of a single chain of D- or L- amino acids or a mixture of D- and L-amino acids joined by peptide bonds.
  • complementary refers to the topological compatibility or matching together of interacting surfaces of a probe molecule and its target.
  • the target and its probe can be described as complementary, and furthermore, the contact surface characteristics are complementary to each other.
  • recombinant refers to a human manipulated nucleic acid (e.g. polynucleotide) or a copy or complement of a human manipulated nucleic acid (e.g. polynucleotide), or if in reference to a protein (i.e, a “recombinant protein”), a protein encoded by a recombinant nucleic acid (e.g. polynucleotide).
  • a recombinant expression cassette comprising a promoter operably linked to a second nucleic acid (e.g. polynucleotide) may include a promoter that is heterologous to the second nucleic acid (e.g.
  • a recombinant expression cassette may comprise nucleic acids (e.g. polynucleotides) combined in such a way that the nucleic acids (e.g. polynucleotides) are extremely unlikely to be found in nature.
  • nucleic acids e.g. polynucleotides
  • human manipulated restriction sites or plasmid vector sequences may flank or separate the promoter from the second nucleic acid (e.g. polynucleotide).
  • the term “substituted” is contemplated to include all permissible substituents of organic compounds.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds.
  • Illustrative substituents include, for example, those described below.
  • the permissible substituents can be one or more and the same or different for appropriate organic compounds.
  • the heteroatoms, such as nitrogen can have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
  • substitution or “substituted with” include the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
  • Z 1 ,” “Z 2 ,” “Z 3 ,” and “Z 4 ” are used herein as generic symbols to represent various specific substituents. These symbols can be any substituent, not limited to those disclosed herein, and when they are defined to be certain substituents in one instance, they can, in another instance, be defined as some other substituents.
  • aliphatic refers to a non-aromatic hydrocarbon group and includes branched and unbranched, alkyl, alkenyl, or alkynyl groups.
  • alkyl as used herein is a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t- butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and the like.
  • the alkyl group can also be substituted or unsubstituted.
  • the alkyl group can be substituted with one or more groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below.
  • groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below
  • alkyl is generally used to refer to both unsubstituted alkyl groups and substituted alkyl groups; however, substituted alkyl groups are also specifically referred to herein by identifying the specific substituent(s) on the alkyl group.
  • halogenated alkyl specifically refers to an alkyl group that is substituted with one or more halide, e.g., fluorine, chlorine, bromine, or iodine.
  • alkoxyalkyl specifically refers to an alkyl group that is substituted with one or more alkoxy groups, as described below.
  • alkylamino specifically refers to an alkyl group that is substituted with one or more amino groups, as described below, and the like.
  • alkyl is used in one instance and a specific term such as “alkylalcohol” is used in another, it is not meant to imply that the term “alkyl” does not also refer to specific terms such as “alkylalcohol” and the like.
  • cycloalkyl refers to both unsubstituted and substituted cycloalkyl moieties
  • the substituted moieties can, in addition, be specifically identified herein; for example, a particular substituted cycloalkyl can be referred to as, e.g., an “alkylcycloalkyl.”
  • a substituted alkoxy can be specifically referred to as, e.g., a “halogenated alkoxy”
  • a particular substituted alkenyl can be, e.g., an “alkenylalcohol,” and the like.
  • the practice of using a general term, such as “cycloalkyl,” and a specific term, such as “alkylcycloalkyl,” is not meant to imply that the general term does not also include the specific term.
  • alkoxy as used herein is an alkyl group bound through a single, terminal ether linkage; that is, an “alkoxy” group can be defined as — OZ 1 where Z 1 is alkyl as defined above.
  • alkenyl as used herein is a hydrocarbon group of from 2 to 24 carbon atoms with a structural formula containing at least one carbon-carbon double bond.
  • the alkenyl group can be substituted with one or more groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below.
  • groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described
  • alkynyl as used herein is a hydrocarbon group of 2 to 24 carbon atoms with a structural formula containing at least one carbon-carbon triple bond.
  • the alkynyl group can be substituted with one or more groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below.
  • aryl as used herein is a group that contains any carbon-based aromatic group including, but not limited to, benzene, naphthalene, phenyl, biphenyl, phenoxybenzene, and the like.
  • heteroaryl is defined as a group that contains an aromatic group that has at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorus.
  • non-heteroaryl which is included in the term “aryl,” defines a group that contains an aromatic group that does not contain a heteroatom. The aryl or heteroaryl group can be substituted or unsubstituted.
  • the aryl or heteroaryl group can be substituted with one or more groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein.
  • the term “biaryl” is a specific type of aryl group and is included in the definition of aryl. Biaryl refers to two aryl groups that are bound together via a fused ring structure, as in naphthalene, or are attached via one or more carbon-carbon bonds, as in biphenyl.
  • cycloalkyl as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms.
  • examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
  • heterocycloalkyl is a cycloalkyl group as defined above where at least one of the carbon atoms of the ring is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
  • the cycloalkyl group and heterocycloalkyl group can be substituted or unsubstituted.
  • the cycloalkyl group and heterocycloalkyl group can be substituted with one or more groups including, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein.
  • Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
  • heterocycloalkenyl is a type of cycloalkenyl group as defined above, and is included within the meaning of the term “cycloalkenyl,” where at least one of the carbon atoms of the ring is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
  • the cycloalkenyl group and heterocycloalkenyl group can be substituted or unsubstituted.
  • the cycloalkenyl group and heterocycloalkenyl group can be substituted with one or more groups including, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein.
  • cyclic group is used herein to refer to either aryl groups, non-aryl groups i.e., cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups), or both. Cyclic groups have one or more ring systems that can be substituted or unsubstituted. A cyclic group can contain one or more aryl groups, one or more non-aryl groups, or one or more aryl groups and one or more non-aryl groups.
  • aldehyde as used herein is represented by the formula — C(O)H. Throughout this specification “C(O)” or “CO” is a short hand notation for C ⁇ O.
  • amine or “amino” as used herein are represented by the formula — NZ’Z 2 .
  • Z 1 and Z 2 can each be substitution group as described herein, such as hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.
  • carboxylic acid as used herein is represented by the formula — C(O)OH.
  • a “carboxylate” or “carboxyl” group as used herein is represented by the formula — C(O)O’-
  • esters as used herein is represented by the formula — OC(O)Z 1 or — C(O)OZ 1 , where Z 1 can be an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.
  • ether as used herein is represented by the formula Z'OZ 2 , where Z 1 and Z 2 can be, independently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.
  • ketone as used herein is represented by the formula Z 1 C(O)Z 2 , where Z 1 and Z 2 can be, independently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.
  • halide or “halogen” as used herein refers to the fluorine, chlorine, bromine, and iodine.
  • hydroxyl as used herein is represented by the formula — OH.
  • nitro as used herein is represented by the formula — NO2.
  • sil as used herein is represented by the formula — SiZ ⁇ Z 3 , where Z 1 , Z 2 , andZ 3 can be, independently, hydrogen, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.
  • sulfonyl is used herein to refer to the sulfo-oxo group represented by the formula — S(O)2Z 1 , where Z 1 can be hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.
  • sulfonylamino or “sulfonamide” as used herein is represented by the formula — S(O)2NH — .
  • phosphonyl is used herein to refer to the phospho-oxo group represented by the formula — P(O)(OZ 1 )2, where Z 1 can be hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.
  • R 1 ,” “R 2 ,” “R 3 ,” “R n ,” etc., where n is some integer, as used herein can, independently, possess one or more of the groups listed above.
  • R 1 is a straight chain alkyl group
  • one of the hydrogen atoms of the alkyl group can optionally be substituted with a hydroxyl group, an alkoxyl group, an amine group, an alkyl group, a halide, and the like.
  • a first group can be incorporated within second group or, alternatively, the first group can be pendant (i.e.. attached) to the second group.
  • an alkyl group comprising an amino group the amino group can be incorporated within the backbone of the alkyl group.
  • the amino group can be attached to the backbone of the alkyl group.
  • the nature of the group(s) that is (are) selected will determine if the first group is embedded or attached to the second group.
  • ionizable lipid refers to a lipid with a group or atom that can be charged (ionized) dependent upon the pH of the environment. Typically, the charge of a primary, secondary and tertiary amines is dependent upon the pH of the system. At low pH levels, these amines tend to be strongly cationic. At high pH levels these amines do not ionize.
  • a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, e.g., each enantiomer, diastereomer, and meso compound, and a mixture of isomers, such as a racemic or scalemic mixture.
  • Described herein are compounds of lipids. In some embodiments, described herein are compounds of Formula I:
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; x and y are independently an integer from 1 to 15;
  • R 1 is independently for each occurrence linear or cyclic alkyl, alkenyl , or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons;
  • the compound of Formula I is defined by one of formulae la-
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; x and y are independently an integer from 1 to 15; R 1 is independently for each occurrence linear or cyclic alkyl, alkenyl , or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons; and
  • the compound of Formula I is a compound of formula la.
  • the lipid compound is a compound of formula lb.
  • the lipid compound is a compound of formula Ic.
  • the lipid compound is a compound of formula Id. In some embodiments, the lipid compound is a compound of formula le. In some embodiments, the lipid compound is a compound of formula If. In some embodiments, the lipid compound is a compound of formula Ig.
  • R 1 is a linear C3-C25 alkyl or cycloalkyl. In some embodiments, R 1 is a linear C3-C25 alkynyl or cycloalkynyl. In some embodiments, R 1 is a linear C3-C25 alkenyl or cycloalkenyl. In some embodiments, R 1 is a branched C 6 -C40 alkyl. In some embodiments, R 1 is a branchedC 6 -C40 alkenyl. For example, in some embodiments, R 1 has the following structures: In some embodiments, the lipid compound of Formula I is selected from:
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; m, n, x, and y are independently an integer from 1 to 15;
  • R 1 and R 2 are independently for each occurrence linear or cyclic alkyl, alkenyl, or alkynyl comprising of 3 to 25 carbons, or branched alkyl or alkenyl comprising of 6 to 40 carbons;
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; m, n, x, and y are independently an integer from 1 to 15;
  • R 1 and R 2 are independently for each occurrence linear or cyclic alkyl, alkenyl, or alkynyl consisting of 3 to 25 carbons, or a branched alkyl or alkenyl consisting of 6 to 40 carbons; and
  • the lipid compound is a compound of formula Ila.
  • the lipid compound is a compound of formula lib.
  • the lipid compound is a compound of formula lie.
  • the lipid compound is a compound of formula lid.
  • the lipid compound is a compound of formula lie.
  • R 1 is a linear C3-C25 alkyl or C3-C25 cycloalkyl. In some embodiments, R 1 is a linear C3-C25 alkynyl or C3-C25 cycloalkynyl. In some embodiments, R 1 is a linear C3-C25 alkenyl or C3-C25 cycloalkenyl. In some embodiments of Formula II, R 1 is a branched -CC 6 40 alkyl. In some embodiments, R 1 is a branched -C40 alkenyl. For exCa 6 mple, in some embodiments of Formula II, R 1 has the following structures:
  • R 1 is -CR b R c .
  • R b and R c are C3 alkyl.
  • R b and R c are C4 alkyl.
  • R 1 is -CR b R c
  • R b and R c are Ci, alkyl.
  • R 1 is -CR b R c , then R b and R c are Cx alkyl.
  • R 1 when R 1 is -CR b R c , then R b and R c are C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C5 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is Cx alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C10 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , R b is Ci alkyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C34 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C39 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C4 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C14 alkyl. In some embodiments, R b is C2 alkyl and R c is Ci6 alkyl. In some embodiments, when R 1 is - CR b R c , then R b is C2 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C38 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C3 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C4 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is Ce alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is Cs alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is Ci6 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C32 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C37 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cs alkyl.
  • R 1 when R 1 is -CR b R c , then R b C 6 alkyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cie alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C32 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b Cx alkyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkyl and R c is Ci6 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cio alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkyl and R c is C20 alkyl. In some embodiments, vhen R 1 is -CR b R c , then R b is Cio alkyl and I c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cio alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is Ci6 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cu alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cu alkyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C5 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is Cx alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is Cio alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is Ci6 alkyl, when R 1 is -CR b R c , then In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Cx alkyl. In some embodiments, when R 1 is - CR b R c , then R c is C2 alkyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C28 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C3 alkyl. In some embodiments, when R 1 is - CR b R c , then R c is C3 alkyl and R b is C4 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is G, alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C37 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is Ci8 alkyl. In some embodiments, when R 1 is - CR b R c , then R c is C 6 alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C34 alkyl. In some embodiments, when R 1 is - CR b R c , then R c Cg alkyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cg alkyl and R b is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Cg alkyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cg alkyl and R b is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cg alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cg alkyl and R b is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b and R c are C3 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then
  • R b and R c are Cx alkenyl. In some embodiments, when R 1 is -CR b R c , then R 1 is -CR b R c and R b and R c are C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R 1 is -CR b R c and R b and R c are C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are Cis alkenyl. In some embodiments,
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C36 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C39 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C 6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkenyl and R c is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkenyl and R c is Cie alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C38 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C3 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is Cx alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C37 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is CY, alkenyl and R c is Cx alkenyl.
  • R 1 when R 1 is -CR b R c , then R b C 6 alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cie alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b Cx alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cx alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is Cie alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkenyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C14 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkenyl and R b is C5 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkenyl and R b is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C10 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Cis alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C26 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C34 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C39 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C4 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cx alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C12 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C36 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Cx alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C22 alkenyl.
  • R c when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C37 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c C 6 alkenyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c Cs alkenyl and R b is C 10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cx alkenyl and R b is C12 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is Cie alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C20 alkenyl.
  • R c when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C10 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C22 alkenyl.
  • R c when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C14 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkenyl and R b is C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C16 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkenyl and R b is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C5 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C10 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is Cis alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C26 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C34 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C39 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C4 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is Cis alkenyl, In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C20 alkenyl, In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkyl and R c is C 36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkyl and R c is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c IS C 3 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 3 alkyl and R c IS C 4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c IS C 8 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C10 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is Cis alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C6 alkyl and R is Cis alkenyl. In some embodiments, when R is -CR b R c , then R b is C 6 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C?x alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ce alkyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ce alkyl and R c is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Q> alkyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b Cx alkyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cx alkyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is Cu alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is Cis alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C26 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is Cu alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is C16 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is Cis alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is CM alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is C26 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cis alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C5 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C 8 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C10 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C26 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C39 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C4 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is Ci> alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 2 alkyl and R b is Cio alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 2 alkyl and R b is C12 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 2 alkyl and R b is C 22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 2 alkyl and R b is C 2 4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 2 alkyl and R b is C 2 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 2 alkyl and R b is C 2 s alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 2 alkyl and R b is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C3 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C 6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is Cio alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is C-- 2 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 3 alkyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 3 alkyl and R b is C37 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C32 alkenyl.
  • R 1 is -CR b R c
  • R c is Cs alkyl and R b is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C10 alkyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is Cie alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is Cis alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C10 alkyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C26 alkenyl.
  • R c when R 1 -CR b R c , then R c is Cio alkyl and R b C28 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is Cio alkyl and R b C30 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C12 alkyl and C14 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C12 alkyl and Ci6 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C12 alkyl and Cis alkenyl.
  • R c when R 1 -CR b R c , then R c is C12 alkyl and C20 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C12 alkyl and C22 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C12 alkyl and C24 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C12 alkyl and C26 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C12 alkyl and C28 alkenyl.
  • R c when R 1 -CR b R c , then R c is C14 alkyl and Ci6 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C14 alkyl and Cis alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C14 alkyl and C20 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C14 alkyl and C22 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is C14 alkyl and R b is C24 alkenyl.
  • R 1 -CR b R c when R 1 -CR b R c , then R c is C14 alkyl and R b is C26 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is Ci6 alkyl and R b is Cis alkenyl. In some embodiments, when R 1 -CR b R c , then R c is Ci6 alkyl and R b is C20 alkenyl. In some embodiments, when R 1 -CR b R c , then R c is Ci6 alkyl and R b is C22 alkenyl.
  • R c when R 1 -CR b R c , then R c is Ci6 alkyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkyl and R b is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkenyland R c is C5 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Cio alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is alkenyl and R c is C 2 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C 32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is alkenyl and R c is C34 alkyl.
  • R 1 when R 1 is -CR b R c , then R b IS C 1 alkenyl and R c is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C39 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 4 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R‘ is C 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is Ci 2 alkyl.
  • R 1 when R 1 is -CR b R c , then R b IS C 2 alkenyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C18 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 2 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C28 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C36 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C 3 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C 4 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is alkenyl and R c is C 6 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C8 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C 36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C37 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 6 alkenyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is alkenyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C32 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkenyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkenyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkenyl and R c is Ci6 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cio alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cio alkenyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is Ci8 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is Cie alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkenyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkenyl and R b is C5 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C12 alkyl.
  • R c when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C20 alkyl.
  • R c when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C28 alkyl.
  • R c when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C36 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C39 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C4 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C 6 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C38 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C3 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C4 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Cs alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Ci6 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C24 alkyl.
  • R c when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C32 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C37 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Cs alkyl.
  • R 1 when R 1 is -CR b R c , then R c C 6 alkenyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R is C 6 alkenyl and R is Cie alkyl.
  • R c when R is -CR b R c , then R c is C 6 alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ce alkenyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ce alkenyl and R b is C32 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Q> alkenyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c Cs alkenyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R is Cs alkenyl and R is Ci6 alkyl. In some embodiments, when R is -CR b R c , then R c is Cs alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C24 alkyl.
  • R c when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C32 alkyl.
  • R 1 and R 2 are the same, in some embodiments, R 1 and R 2 are different.
  • R 1 is a linear or cyclic alkyl, alkenyl, or alkynyl consisting of 3 to 25 carbons, or a branched alkyl or alkenyl consisting of 6 to 40 carbons and R 2 is -CR b R c .
  • R 1 is a linear or cyclic alkyl, alkenyl, or alkynyl consisting of 3 to 25 carbons and R 2 is -CR b R c .
  • R 1 is a branched alkyl or alkenyl consisting of 6 to 40 carbons and R 2 is -CR b R c .
  • R 1 and R 2 are each independently -CR b R c . In some embodiments of Formula II, R 1 and R 2 are the same -CR b R c . In some embodiments of Formula II, R 1 and R 2 are the different -CR b R c .
  • R 2 is -CR b R c .
  • R b and R c are C3 alkyl.
  • R b and R c are C4 alkyl.
  • R b and R c are C 6 alkyl.
  • R b and R c are Cs alkyl.
  • R b and R c are C10 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci alkyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci alkyl and R c is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci alkyl and R c is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci alkyl and R c is Cis alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci alkyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci alkyl and R c is C26 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci alkyl and R c is C28 alkyl. In some embodiments, R b is Ci alkyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci alkyl and R c is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci alkyl and R c is C36 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci alkyl and R c is C38 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci alkyl and R c is C39 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C4 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C 6 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkyl and R c is Cx alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C14 alkyl. In some embodiments, R b is C2 alkyl and R c is Ci6 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkyl and R c is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C24 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkyl and R c is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C32 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is Cis alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C26 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkyl and R c is C36 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C37 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is Cx alkyl. In some embodiments, when R 2 is - CR b R c , then R b C 6 alkyl and R c is C10 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is Cis alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C24 alkyl. In some embodiments, when R 2 is - CR b R c , then R b is C 6 alkyl and R c is C26 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C34 alkyl.
  • R 2 when R 2 is -CR b R c , then R b Cs alkyl and R c is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C14 alkyl. In some embodiments, when R 2 is - CR b R c , then R b is Cs alkyl and R c is Cie alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Cs alkyl and R c is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C24 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Cs alkyl and R c is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C30 alkyl. In some embodiments, when R 2 is - CR b R c , then R b is Cs alkyl and R c is C32 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C10 alkyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is Cis alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C10 alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkyl and R c is C26 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Cio alkyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is Ci6 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C12 alkyl and R c is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C24 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C12 alkyl and R c is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkyl and R c is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkyl and R c is Cis alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Cu alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cu alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkyl and R c is C26 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci6 alkyl and R c is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkyl and R c is C24 alkyl.
  • R b when R 2 is -CR b R c , then R b is Cis alkyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cis alkyl and R c is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is Ci alkyl and R b is C5 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C 6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is Cx alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is Cio alkyl.
  • R c when R 2 is -CR b R c , then R c is Ci alkyl and R b is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is Cis alkyl.
  • R c when R 2 is -CR b R c , then R c is Ci alkyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is C26 alkyl.
  • R c when R 2 is -CR b R c , then R c is Ci alkyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is C34 alkyl.
  • R c when R 2 is -CR b R c , then R c is Ci alkyl and R b is C36 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C38 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci alkyl and R b is C39 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C4 alkyl.
  • R 1 is - CR b R c
  • R c is C2 alkyl and R b is C 6 alkyl.
  • R 2 is -CR b R c
  • R c is C2 alkyl and R b is Cs alkyl.
  • R c is C2 alkyl and R b is C10 alkyl.
  • R c is C2 alkyl and R b is C12 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkyl and R b is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C20 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C28 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C36 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkyl and R b is C38 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C3 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C4 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is G, alkyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkyl and R b is Cs alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C14 alkyl.
  • R 2 when R 2 is -CR b R c , then R c is C3 alkyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C30 alkyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C36 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C37 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkyl and R b is Cs alkyl. In some embodiments, when R 2 is -CR b R c , then R c C 6 alkyl and R b is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C14 alkyl.
  • R 2 when R 2 is -CR b R c , then R c is C 6 alkyl and R b is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C28 alkyl. In some embodiments, when R 2 is - CR b R c , then R c is C 6 alkyl and R b is C30 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R c Cs alkyl and R b is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C12 alkyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkyl and R b is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is Cis alkyl. In some embodiments, when R 2 is - CR b R c , then R c is Cs alkyl and R b is C20 alkyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C28 alkyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is C14 alkyl.
  • R c when R 2 is -CR b R c , then R c is C10 alkyl and R b is C16 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkyl and R b is
  • R c is Cio alkyl and R b is C24 alkyl.
  • R c when R 2 is -CR b R c , then R c is Cio alkyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkyl and R b is C 28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C14 alkyl.
  • R c when R 2 is -CR b R c , then R c is C12 alkyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is C12 alkyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C 26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkyl and R b is Ci6 alkyl.
  • R 2 when R 2 is -CR b R c , then R c is C14 alkyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkyl and R b is C24 alkyl.
  • R c when R 2 is -CR b R c , then R c is C14 alkyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkyl and R b is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is Ci6 alkyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cis alkyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cis alkyl and R b is C22 alkyl.
  • R 2 when R 2 is -CR b R c , then R b and R c are C3 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b and R c are C4 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b and R c are C 6 alkenyl. In some embodiments, when R 2 is -CR b R c , then
  • R b and R c are Cx alkenyl.
  • R 1 is -CR b R c and R b and R c are Cio alkenyl.
  • R 1 is -CR b R c and R b and R c are C12 alkenyl.
  • R b and R c are C14 alkenyl.
  • R b and R c are C16 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b and R c are Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b and R c are C20 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci alkenyl and R c is C5 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci alkenyl and R c is C 6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is Cx alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C12 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C20 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C28 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C36 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C38 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C39 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C4 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C 6 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkenyl and R c is Cx alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C14 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkenyl and R c is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C30 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C36 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C38 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C3 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C4 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C ⁇ > alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is Cx alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is Cie alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C24 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C36 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C37 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is Cs alkenyl.
  • R 2 when R 2 is -CR b R c , then R b C 6 alkenyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is Cie alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C24 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C32 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b Cx alkenyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkenyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cx alkenyl and R c is C14 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Cx alkenyl and R c is Cie alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkenyl and R c is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Cs alkenyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkenyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkenyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkenyl and R c is C30 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Cs alkenyl and R c is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is Ci6 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C10 alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C24 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C14 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C16 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkenyl and R c is Ci6 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C14 alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkenyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkenyl and R c is C24 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C14 alkenyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkenyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkenyl and R c is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci6 alkenyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cis alkenyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cis alkenyl and R c is C22 alkenyl.
  • R c is Ci alkenyl and R b is C5 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Ci alkenyl and R b is C 6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C12 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C20 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C28 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C36 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C38 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C39 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C4 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C 6 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C14 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C22 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C30 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C36 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C38 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C3 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C4 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is CV, alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is Cs alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is Ci6 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C24 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C32 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C36 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C37 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is Cs alkenyl.
  • R 2 when R 2 is -CR b R c , then R c C 6 alkenyl and R b is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is Ci6 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C24 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C32 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c Cs alkenyl and R b is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cx alkenyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cx alkenyl and R b is C14 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C22 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C30 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkenyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkenyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkenyl and R b is Ci6 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Cio alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkenyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkenyl and R b is C24 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Cio alkenyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkenyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cio alkenyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C14 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C12 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C22 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkenyl and R b is Ci6 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C14 alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkenyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkenyl and R b is C24 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C14 alkenyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkenyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkenyl and R b is C22 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Ci6 alkenyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cis alkenyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cis alkenyl and R b is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci alkyl and R c is C5 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C 6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is Cio alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is Cis alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C26 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C34 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C36 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C38 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkyl and R c is C39 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C4 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkyl and R c is Ce alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C12 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkyl and R c is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is Ci8 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C20 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C28 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkyl and R c is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkyl and R c is C36 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C2 alkyl and R c is C38 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C3 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C4 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C 6 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkyl and R c is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C14 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C30 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkyl and R c is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C36 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkyl and R c is C37 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkyl and R c is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R b C 6 alkyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C14 alkenyl.
  • R 2 when R 2 is -CR b R c , then R is C 6 alkyl and R is Ci6 alkenyl. In some embodiments, when R is -CR b R c , then R b is C 6 alkyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C24 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C32 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkyl and R c is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b Cs alkyl and R c is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C14 alkenyl.
  • R 2 when R 2 is -CR b R c , then R is Cs alkyl and R is Ci6 alkenyl. In some embodiments, when R is -CR b R c , then R b is Cx alkyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cx alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Cs alkyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cs alkyl and R c is C30 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Cs alkyl and R c is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is Ci6 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C10 alkyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C24 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C10 alkyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkyl and R c is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C14 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C12 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is Ci8 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C12 alkyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkyl and R c is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkyl and R c is Ci6 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C14 alkyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkyl and R c is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkyl and R c is C24 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is C 14 alkyl and R c is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkyl and R c is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkyl and R c is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci6 alkyl and R c is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cis alkyl and R c is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R b is Cis alkyl and R c is C22 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Ci alkyl and R b is C5 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C 6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C10 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is Cis alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C26 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C34 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C36 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C38 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkyl and R b is C39 alkenyl.
  • R 2 when R 2 is -CR b R c , then R c is C2 alkyl and R b is C4 alkenyl, In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C 6 alkenyl, In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C10 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is Cis alkenyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C26 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C34 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkyl and R b is C36 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkyl and R b is C38 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C3 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C4 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkyl and R b is Ce alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C12 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C20 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C28 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C32 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkyl and R b is C36 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkyl and R b is C37 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is Cs alkenyl. In some embodiments, when R 2 is -CR b R c , then R c C 6 alkyl and R b is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C12 alkenyl.
  • R 2 when R 2 is -CR b R c , then R c is C 6 alkyl and R b is Cu alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ce alkyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ce alkyl and R b is
  • R c is C 6 alkyl and R b is C24 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ce alkyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C32 alkenyl.
  • R 2 when R 2 is -CR b R c , then R c is C 6 alkyl and R b is C34 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c Cs alkyl and R b is C10 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C14 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R is Cis alkenyl. In some embodiments, when R is -CR b R c , then R c is Cs alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is
  • R c is Cs alkyl and R b is C24 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkyl and R b is C32 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C10 alkyl and R b is C12 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is Cis alkenyl.
  • R c when R 2 is -CR b R c , then R c is C10 alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is C26 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C10 alkyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkyl and R b is C30 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C14 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is Ci6 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C12 alkyl and R b is Cis alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C24 alkenyl.
  • R c when R 2 is -CR b R c , then R c is C12 alkyl and R b is C26 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkyl and R b is C28 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkyl and R b is Ci6 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkyl and R b is Cis alkenyl.
  • R c when R 2 is -CR b R c , then R c is C14 alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkyl and R b is C24 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is C 14 alkyl and R b is C26 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Ci6 alkyl and R b is Ci8 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkyl and R b is C22 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkyl and R b is C24 alkenyl.
  • R c when R 2 is -CR b R c , then R c is Cis alkyl and R b is C20 alkenyl. In some embodiments, when R 2 is -CR b R c , then R c is Cis alkyl and R b is C22 alkenyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci alkenyland R c is C5 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is G, alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is Cs alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C10 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is Cis alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C26 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C34 alkyl.
  • R 2 -CR b R c when R 2 -CR b R c , then R b is alkenyl and R c is C 3 6 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is alkenyl and R c is C38 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C39 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C 4 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C 6 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R‘ is C 8 alkyl. In some embodiments, when R 2 -CR b R c , then R b is C 2 alkenyl and R c is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C12 alkyl.
  • R 2 -CR b R c when R 2 -CR b R c , then R b is C 2 alkenyl and R c is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 2 -CR b R c , then R b is C 2 alkenyl and R c is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C20 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C2 alkenyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C 26 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C28 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is alkenyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C36 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 2 alkenyl and R c is C 38 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C 3 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 3 alkenyl and is alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 3 alkenyl and R c is C 6 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 3 alkenyl and R c is C 8 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 3 alkenyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C14 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is alkenyl and R c is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 3 alkenyl and R c is C18 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 3 alkenyl and R c is C22 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C30 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C36 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C3 alkenyl and R c is C37 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C 8 alkyl. In some embodiments, when R 2 is -CR b R c , then R b C 6 alkenyl and R c is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C14 alkyl.
  • R 2 when R 2 is -CR b R c , then R is C 6 alkenyl and R is Cie alkyl. In some embodiments, when R is -CR b R c , then R b is C 6 alkenyl and R c is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is
  • R 2 is -CR b R c
  • R b is C 6 alkenyl and R c is C24 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C32 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 6 alkenyl and R c is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R b Cs alkenyl and R c is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is C14 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is Ci 8 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is
  • R 2 is -CR b R c
  • R b is Cx alkenyl and R c is C24 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is C 28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 8 alkenyl and R c is C32 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C10 alkenyl and R c is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C10 alkenyl and R c is Cu alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkenyl and R c is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkenyl and R c is Cis alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Cio alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkenyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkenyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkenyl and R c is C26 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Cio alkenyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cio alkenyl and R c is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is Ci6 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C12 alkenyl and R c is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C24 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C12 alkenyl and R c is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is CM alkenyl and R c is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkenyl and R c is Cis alkyl.
  • R 2 when R 2 is -CR b R c , then R b is C14 alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkenyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C14 alkenyl and R c is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is C 1 alkenyl and R c is C26 alkyl.
  • R 2 when R 2 is -CR b R c , then R b is Ci6 alkenyl and R c is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkenyl and R c is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Ci6 alkenyl and R c is C24 alkyl.
  • R b when R 2 is -CR b R c , then R b is Cis alkenyl and R c is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R b is Cis alkenyl and R c is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is Ci alkenyl and R b is C5 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C 6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is Cs alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is Cio alkyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is CM alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is Cis alkyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C26 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C34 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C36 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C38 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 1 alkenyl and R b is C39 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C4 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C 6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is Cs alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C12 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C14 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C20 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C28 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C36 alkyl.
  • R c when R 2 is -CR b R c , then R c is C2 alkenyl and R b is C38 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C3 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C4 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C 6 alkyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is Cs alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C 14 alkyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C30 alkyl.
  • R c when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C36 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C3 alkenyl and R b is C37 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is Cs alkyl. In some embodiments, when R 2 is -CR b R c , then R c C 6 alkenyl and R b is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C14 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C24 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C32 alkyl.
  • R c when R 2 is -CR b R c , then R c is C 6 alkenyl and R b is C34 alkyl. In some embodiments, when R 2 is -CR b R c , then R c Cs alkenyl and R b is C10 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C12 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C14 alkyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkenyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is
  • R c is Cs alkenyl and R b is C18 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C26 alkyl.
  • R c when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cs alkenyl and R b is C32 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkenyl and R b is C12 alkyl. In some embodiments, R c is C10 alkenyl and R b is C14 alkyl.
  • R c when R 2 is -CR b R c , then R c is C10 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkenyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkenyl and R b is
  • R c is C10 alkenyl and R b is C24 alkyl.
  • R c when R 2 is -CR b R c , then R c is C10 alkenyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkenyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C10 alkenyl and R b is C30 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C14 alkyl.
  • R c when R 2 is -CR b R c , then R c is C12 alkenyl and R b is Cie alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C12 alkenyl and R b is C28 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkenyl and R b is Ci6 alkyl.
  • R c when R 2 is -CR b R c , then R c is C14 alkenyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkenyl and R b is C22 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C14 alkenyl and R b is C24 alkyl.
  • R c when R 2 is -CR b R c , then R c is C14 alkenyl and R b is C26 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is C16 alkenyl and R b is Cis alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Ci6 alkenyl and R b is C22 alkyl.
  • R c when R 2 is -CR b R c , then R c is C16 alkenyl and R b is C24 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cis alkenyl and R b is C20 alkyl. In some embodiments, when R 2 is -CR b R c , then R c is Cis alkenyl and R b is C22 alkyl.
  • R 2 is -C 6 Hn, -C7H15, -CsHn, -C10H21, -C11H23, -C12H25, -C13H27,
  • the lipid compound of Formula II is selected from: or any combination thereof.
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; x and y are independently an integer from 1 to 15;
  • R 1 is independently for each occurrence a linear or cyclic alkyl, alkenyl , or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons;
  • the compound of Formula III is defined by one of formulae Illa-IIIf: or a pharmaceutically acceptable salt thereof, wherein:
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; m, x, and, y are independently an integer from 1 to 15; R 1 is independently for each occurrence linear or cyclic alkyl, alkenyl, or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons; and
  • the compound of Formula III the lipid compound has structure Illa.
  • the lipid compound is a compound of formula Illb.
  • the lipid compound is a compound of formula IIIc.
  • the lipid compound is a compound of Hid.
  • the lipid compound is a compound of formula Hie.
  • the lipid compound is a compound of formula Illf.
  • R 1 is a linear C3-C25 alkyl or cycloalkyl. In some embodiments, R 1 is a linear C3-C25 alkynyl or cycloalkynyl. In some embodiments, R 1 is a linear C3-C25 alkenyl or cycloalkenyl. In some embodiments, R 1 is a branched -C40 alkyl. ICn 6 some embodiments, R 1 is a branched C-C 6 40 alkenyl. For example, in some embodiments, R 1 has the following structures: In some embodiments, the lipid compound of Formula III is selected from:
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; m, x, and y are independently an integer from 1 to 15;
  • R 1 is independently for each occurrence linear or cyclic alkyl, alkenyl, or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons;
  • the compound of Formula IV is defined by one of formulae
  • IVd IVe or a pharmaceutically acceptable salt thereof, wherein: R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; m, x, and y are independently an integer from 1 to 15;
  • R 1 is independently for each occurrence linear or cyclic alkyl, alkenyl, or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons;
  • the compound of Formula IV is a compound of formula Iva. In some embodiments, the lipid compound is a compound of formula IVb. In some embodiments, the lipid compound is a compound of formula IVc. In some embodiments, the lipid compound is a compound of formula IVd. In some embodiments, the lipid compound is a compound of formula IVe.
  • R 1 is a linear C3-C25 alkyl or cycloalkyl. In some embodiments, R 1 is a linear C3-C25 alkynyl or cycloalkynyl. In some embodiments, R 1 is a linear C3-C25 alkenyl or cycloalkenyl. In some embodiments, R 1 is a branched -C40 alkyl. In C 6 some embodiments, R 1 is a branched -C40 alkenCyl 6 . For example, in some embodiments, R 1 has the following structures:
  • the lipid compound of Formula IV is selected from:
  • R a is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; i, j, k, p, q, and r are independently 0, 1, 2, 3 or 4; m, x, y, and z are independently an integer from 1 to 15;
  • R 1 is independently for each occurrence linear or cyclic alkyl, alkenyl, or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons;
  • R 4 is absent. In some embodiments, R 4 is -S-S-.
  • R a is a H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl. In some embodiments, R a is a H. In some embodiments, R a is a C 1 -C 6 alkyl. In some embodiments, R a is a C 1 -C 6 alkenyl.
  • the compound of Formula V is selected from: Described herein are compounds of Formula VI: or a pharmaceutically acceptable salt thereof, wherein:
  • R 5 is -S-S-
  • R b is H, C 1 -C 6 alkyl or C 1 -C 6 alkenyl; p, q, and r are independently 0, 1, 2, 3 or 4; m, x, and y are independently an integer from 1 to 15; R 1 is independently for each occurrence linear or cyclic alkyl, alkenyl, or alkynyl comprising of 3 to 25 carbons, or a branched alkyl or alkenyl comprising of 6 to 40 carbons; and
  • the compound of Formula VI is selected from: combination thereof.
  • R b is a H.
  • R b is a C 1 -C 6 alkyl.
  • R b is a C 1 -C 6 alkenyl.
  • R 1 is -CR b R c .
  • R b and R c are C3 alkyl.
  • R b and R c are C4 alkyl.
  • R 1 is -CR b R c
  • R b and R c are C 6 alkyl.
  • R 1 is -CR b R c , then R b and R c are Cx alkyl.
  • R 1 when R 1 is -CR b R c , then R b and R c are Cio alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C5 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is Cx alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is Cio alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , R b is Ci alkyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C34 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci alkyl and R c is C39 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C4 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is Cio alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C14 alkyl. In some embodiments, R b is C2 alkyl and R c is Cie alkyl. In some embodiments, when R 1 is - CR b R c , then R b is C2 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C38 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C3 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C4 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is Cx alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is Ci6 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C32 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C37 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cx alkyl.
  • R 1 when R 1 is -CR b R c , then R b C 6 alkyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cie alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C32 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ce alkyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b Cs alkyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkyl and R c is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and
  • R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cu alkyl and R c is C16 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C14 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cu alkyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C14 alkyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci6 alkyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C5 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is Ce alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C10 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is Ci6 alkyl, when R 1 is -CR b R c , then In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C34 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkyl and R b is C39 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C4 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Cs alkyl. In some embodiments, when R 1 is - CR b R c , then R c is C2 alkyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C28 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C36 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C3 alkyl. In some embodiments, when R 1 is - CR b R c , then R c is C3 alkyl and R b is C4 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C 6 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C37 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c C 6 alkyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is - CR b R c , then R c is C 6 alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ce alkyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C34 alkyl. In some embodiments, when R 1 is - CR b R c , then R c Cs alkyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C24 alkyl. In some embodiments, when R 1 is - CR b R c , then R c is Cs alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C28 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C10 alkyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C10 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C12 alkyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and R b is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C12 alkyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and R b is C28 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Cu alkyl and R b is C16 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C14 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkyl and R b is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci6 alkyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b and R c are C3 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then
  • R b and R c are Cx alkenyl. In some embodiments, when R 1 is -CR b R c , then R 1 is -CR b R c and R b and R c are C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R 1 is -CR b R c and R b and R c are C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b and R c are Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b and R c are C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkenyl and R c is C5 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkenyl and R c is Ce alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Cx alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C12 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C36 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C39 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C 6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkenyl and R c is Cx alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkenyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkenyl and R c is C38 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C3 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is Cx alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C37 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cs alkenyl.
  • R 1 when R 1 is -CR b R c , then R b C 6 alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cie alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b Cs alkenyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is Cie alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkenyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C14 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C16 alkenyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkenyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkenyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci alkenyl and R b is C5 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkenyl and R b is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C12 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C36 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C39 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C 6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cie alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C38 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C3 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Cx alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C37 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Cs alkenyl.
  • R 1 when R 1 is -CR b R c , then R c C 6 alkenyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Cie alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c Cx alkenyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cx alkenyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cx alkenyl and R b is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C22 alkenyl.
  • R c when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C10 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C24 alkenyl.
  • R c when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C12 alkenyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C22 alkenyl.
  • R c when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is Ci6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C14 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkenyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkenyl and R b is C22 alkenyl.
  • R c when R 1 is -CR b R c , then R c is Ci6 alkenyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkenyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkenyl and R b is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkyl and R c is C5 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C10 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is Cis alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C26 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C34 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkyl and R c is C39 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C4 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C 6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C12 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C2 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C2 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkyl and R c is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkyl and R c is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkyl and is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkyl and R c is C 36 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkyl and is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c IS C 3 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C 4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c IS C 6 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C 8 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b IS C 3 alkyl and R c IS C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 3 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkyl and R c is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkyl and R c is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then is C 3 alkyl and R c is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then is C 3 alkyl and R c is C 36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkyl and R c is C 3 7 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R b C 6 alkyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cie alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C2 8 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C 3 o alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C 3 2 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkyl and R c is C 3 4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b C 8 alkyl and R c is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C12 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 8 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 8 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C 3 o alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C 8 alkyl and R c is C 3 2 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkyl and R c is C16 alkenyl. some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkyl and R c is C22 alkenyl.
  • R 1 -CR b R c when R 1 -CR b R c , then R b is Cio alkyl and R c is C24 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is Cio alkyl and R c is C26 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is Cio alkyl and R c is C28 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is Cio alkyl and R c is C30 alkenyl.
  • R 1 -CR b R c when R 1 -CR b R c , then R b is C12 alkyl and R c is CM alkenyl. In some embodiments, when R 1 -CR b R c , then R b is C12 alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is C12 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 -CR b R c , then R b is C12 alkyl and R c is C20 alkenyl.
  • R 1 -CR b R c when R 1 -CR b R c , then R b is C12 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is C12 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is C12 alkyl and R c is C26 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is C12 alkyl and R c is C28 alkenyl.
  • R 1 -CR b R c when R 1 -CR b R c , then R b is CM alkyl and R c is Ci6 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is CM alkyl and R c is Cis alkenyl. In some embodiments, when R 1 -CR b R c , then R b is C14 alkyl and R c is C20 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is CM alkyl and R c is C22 alkenyl.
  • R 1 -CR b R c when R 1 -CR b R c , then R b is CM alkyl and R c is C24 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is C14 alkyl and R c is C26 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is Ci6 alkyl and R c is Cis alkenyl. In some embodiments, when R 1 -CR b R c , then R b is Ci6 alkyl and R c is C20 alkenyl.
  • R 1 -CR b R c when R 1 -CR b R c , then R b is Ci6 alkyl and R c is C22 alkenyl. In some embodiments, when R 1 -CR b R c , then R b is Ci6 alkyl and R c is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkyl and R c is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkyl and R c is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is Ce alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is Cio alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is Cis alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C26 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C34 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkyl and R b is C39 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C4 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C ⁇ > alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C12 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C20 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C28 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 2 alkyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkyl and R b is C36 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkyl and R b is C38 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C3 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C4 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is G, alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 3 alkyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is C16 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C30 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkyl and R b is C32 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C36 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkyl and R b is C37 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is Cs alkenyl. In some embodiments, when R 1 is -CR b R c , then R c C 6 alkyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C14 alkenyl.
  • R 1 when R 1 is -CR b R c , then R is C 6 alkyl and R is Cie alkenyl. In some embodiments, when R is -CR b R c , then R c is C 6 alkyl and R b is Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkyl and R b is C34 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c Cs alkyl and R b is C10 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C12 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is Cu alkenyl.
  • R 1 when R 1 is -CR b R c , then R is Cs alkyl and R is Cie alkenyl. In some embodiments, when R is -CR b R c , then R c is Cs alkyl and R b is C is alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C;, alkyl and R b is C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkyl and R b is C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cs alkyl and R b is C32 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C10 alkyl and R b is C12 alkenyl, In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C14 alkenyl, In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is Ci6 alkenyl, In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is Cis alkenyl, In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C20 alkenyl, In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and R b is C22 alkenyl, In some embodiments, when R 1 is -
  • R c when R 1 is -CR b R c , then R c is C10 alkyl and R b is C28 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkyl and C30 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and C14 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and Cis alkenyl.
  • R c when R 1 is -CR b R c , then R c is C12 alkyl and C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkyl and C28 alkenyl.
  • R c when R 1 is -CR b R c , then R c is C14 alkyl and Ci6 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkyl and Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkyl and C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkyl and C22 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkyl and C24 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is C14 alkyl and R b C26 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkyl and R b Cis alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkyl and C20 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkyl and R b C22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci6 alkyl and R b is C24 alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkyl and R b is C 2 o alkenyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkyl and R b is C 22 alkenyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci alkenyland R c is C5 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Ci, alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is Cio alkyl.
  • R 1 when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C 2 o alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C 22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C 2 4 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C 2 6 alkyl.
  • R 1 when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C 2 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 1 alkenyl and is C3 2 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is alkenyl and R c is C34 alkyl.
  • R 1 when R 1 is -CR b R c , then R b C 1 alkenyl and R c is C 3 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 1 alkenyl and R c is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is alkenyl and R c is C39 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 4 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is Cio alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C1 2 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C16 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c IS Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 2 o alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 2 4 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 2 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C28 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C 36 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 2 alkenyl and R c is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C 3 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C 4 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C 6 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is alkenyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C18 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 3 alkenyl and R c is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C3 alkenyl and R c is C37 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R b C 6 alkenyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C 24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C 6 alkenyl and R c is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R b Cs alkenyl and R c is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cx alkenyl and R c is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is
  • R 1 is -CR b R c
  • R b is Cs alkenyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cs alkenyl and R c is C32 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C10 alkenyl and R c is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is Cie alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkenyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C12 alkenyl and R c is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is CM alkenyl and R c is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is Ci8 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Cu alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is C14 alkenyl and R c is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Ci6 alkenyl and R c is C24 alkyl.
  • R b when R 1 is -CR b R c , then R b is Cis alkenyl and R c is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R b is Cis alkenyl and R c is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Ci alkenyl and R b is C5 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C10 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C34 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 1 alkenyl and R b is C39 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C4 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C 6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C28 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C36 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C2 alkenyl and R b is C38 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C3 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C4 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C 6 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Cs alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C22 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C3 alkenyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 3 alkenyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 3 alkenyl and R b is C36 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 3 alkenyl and R b is C37 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R c C 6 alkenyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C12 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C14 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Cie alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is Ci 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C 2 2 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C 28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C30 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C 32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 6 alkenyl and R b is C34 alkyl. In some embodiments, when R 1 is -CR b R c , then R c C 8 alkenyl and R b is C10 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 8 alkenyl and R b is C12 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Cs alkenyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R is Cs alkenyl and R is Ci6 alkyl. In some embodiments, when R is -CR b R c , then R c is C 8 alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 8 alkenyl and R b is C20 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 8 alkenyl and R b is C 2 2 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 8 alkenyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 8 alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 8 alkenyl and R b is C 28 alkyl.
  • R c when R 1 is -CR b R c , then R c is C 8 alkenyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 8 alkenyl and R b is C32 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C12 alkyl. In some embodiments, R c is C10 alkenyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C16 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C10 alkenyl and R b is Ci 8 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C10 alkenyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cio alkenyl and R b is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is Cio alkenyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cio alkenyl and R b is C30 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 12 alkenyl and R b is C14 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 12 alkenyl and R b is Cie alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C12 alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 12 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 12 alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C12 alkenyl and R b is C24 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 12 alkenyl and R b is C26 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 12 alkenyl and R b is C28 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 14 alkenyl and R b is Ci6 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 14 alkenyl and R b is Cis alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 14 alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 14 alkenyl and R b is C24 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C14 alkenyl and R b is C26 alkyl.
  • R 1 when R 1 is -CR b R c , then R c is C 16 alkenyl and R b is Cis alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 16 alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Ci6 alkenyl and R b is C22 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is C 16 alkenyl and R b is C24 alkyl.
  • R c when R 1 is -CR b R c , then R c is C is alkenyl and R b is C20 alkyl. In some embodiments, when R 1 is -CR b R c , then R c is Cis alkenyl and R b is C22 alkyl.
  • R 1 is -C3H7, -C4H9, -C5H11, -C 6 Hi3, -C7H15, -CsHn, -C10H21, -
  • p, q, and r are independently 0, 1, 2, 3 or 4. In some embodiments, p is 0, 1, 2, 3 or 4. In some embodiments, q is 0, 1, 2, 3 or 4. In some embodiments, r is 0, 1, 2, 3 or 4. In some embodiments, p is 0, q is 0, and r is 0. In some embodiments, p is 0, q is 1, and r is 0. In some embodiments, p is 0, q is 1, and r is 1. In some embodiments, p is 0, q is 1, and r is 2. In some embodiments, p is 0, q is 1, and r is 3. In some embodiments, p is 0, q is 1, and r is 4. In some embodiments, p is 0, q is 2, and r is 3.
  • p is 0, q is 2, and r is 1. In some embodiments, p is 0, q is 2, and r is 2. In some embodiments, p is 0, q is 2, and r is 3. In some embodiments, p is 0, q is 2, and r is 4. In some embodiments, p is 0, q is 3, and r is 0. In some embodiments, p is 0, q is 3, and r is 1. In some embodiments, p is 0, q is 3, and r is 2. In some embodiments, p is 0, q is 3, and r is 3. In some embodiments, p is 0, q is 3, and r is 4. In some embodiments, p is 0, q is 4, and r is 0.
  • p is 0, q is 4, and r is 1. In some embodiments, p is 0, q is 4, and r is 2. In some embodiments, p is 0, q is 4, and r is 3. In some embodiments, p is 0, q is 4, and r is 4. In some embodiments, p is 1, q is 0, and r is 0. In some embodiments, p is 1, q is 1 , and r is 0. In some embodiments, p is 1, q is 1, and r is 1. In some embodiments, p is 1, q is 1 , and r is 2. In some embodiments, p is 1, q is 1, and r is 3. In some embodiments, p is 1, q is 1 , and r is 4.
  • p is 2, q is 1, and r is 1. In some embodiments, p is 2, q is 1 , and r is 2. In some embodiments, p is 2, q is 1, and r is 3. In some embodiments, p is 2, q is 1 , and r is 4. In some embodiments, p is 3, q is 1, and r is 1. In some embodiments, p is 3, q is 1 , and r is 2. In some embodiments, p is 3, q is 1, and r is 3. In some embodiments, p is 3, q is 1 , and r is 4. In some embodiments, p is 4, q is 1, and r is 1. In some embodiments, p is 4, q is 1 , and r is 2.
  • p is 4, q is 1, and r is 3. In some embodiments, p is 4, q is 1 , and r is 4. In some embodiments, p is 1, q is 2, and r is 0. In some embodiments, p is 1, q is 2, and r is 1. In some embodiments, p is 1, q is 2, and r is 2. In some embodiments, p is 1, q is 2, and r is 3. In some embodiments, p is 1, q is 2, and r is 4. In some embodiments, p is 1, q is 3, and r is 0. In some embodiments, p is 1, q is 3, and r is 1. In some embodiments, p is 1 , q is 3, and r is 2.
  • p is 1, q is 3, and r is 3. In some embodiments, p is 1 , q is 3, and r is 4. In some embodiments, p is 2, q is 4, and r is 0. In some embodiments, p is 2, q is 4, and r is 1. In some embodiments, p is 2, q is 4, and r is 2. In some embodiments, p is 2, q is 4, and r is 3. In some embodiments, p is 2, q is 4, and r is 4. In some embodiments, p is 3, q is 2, and r is 0. In some embodiments, p is 3, q is 2, and r is 1. In some embodiments, p is 3, q is 2, and r is 2.
  • p is 3, q is 2, and r is 3. In some embodiments, p is 3, q is 2, and r is 4. In some embodiments, p is 4, q is 3, and r is 0. In some embodiments, p is 4, q is 3, and r is 1. In some embodiments, p is 4, q is 3, and r is 2. In some embodiments, p is 4, q is 3, and r is 3. In some embodiments, p is 4, q is 3, and r is 4. In some embodiments, p is 4, q is 4, and r is 0. In some embodiments, p is 4, q is 4, and r is 1. In some embodiments, p is 4, q is 4, and r is 2.
  • p is 4, q is 4, and r is 3. In some embodiments, p is 4, q is 4, and r is 4. In some embodiments, p is 0 and q is 0. In some embodiments, p is 0 and q is 1. In some embodiments, p is 0 and q is 2. In some embodiments, p is 0 and q is 3. In some embodiments, p is 0 and q is 4. In some embodiments, p is 1 and q is 0. In some embodiments, p is 1 and q is
  • p is 1 and q is 2. In some embodiments, p is 1 and q is 3. In some embodiments, p is 1 and q is 4. In some embodiments, p is 2 and q is 0. In some embodiments, p is 2 and q is 1. In some embodiments, p is 2 and q is 2. In some embodiments, p is 2 and q is 3. In some embodiments, p is 2 and q is 4. In some embodiments, p is 3 and q is 0. In some embodiments, p is 3 and q is 1. In some embodiments, p is 3 and q is 2. In some embodiments, p is 3 and q is 3. In some embodiments, p is 3 and q is 4.
  • p is 4 and q is 0. In some embodiments, p is 4 and q is 1. In some embodiments, p is 4 and q is 2. In some embodiments, p is 4 and q is 3. In some embodiments, p is 4 and q is 4.
  • i, j, and k are independently 0, 1 , 2, 3 or 4. In some embodiments, i is 0, 1, 2, 3 or 4. In some embodiments, j is 0, 1, 2, 3 or 4. In some embodiments, k is 0, 1, 2, 3 or 4. In some embodiments, i is 0, j is 0, and k is 0. In some embodiments, i is 0, j is 1, and k is 0. In some embodiments, i is 0, j is 1, and k is 1. In some embodiments, i is 0, j is 1, and k is
  • i is 0, j is 1, and k is 3. In some embodiments, i is 0, j is 1, and k is 4.
  • i is 0, j is 2, and k is 0. In some embodiments, i is 0, j is 2, and k is 1. In some embodiments, i is 0, j is 2, and k is 2. In some embodiments, i is 0, j is 2, and k is 3. In some embodiments, i is 0, j is 2, and k is 4. In some embodiments, i is 0, j is 3, and k is 0. In some embodiments, i is 0, j is 3, and k is 1. In some embodiments, i is 0, j is 3, and k is 2. In some embodiments, i is 0, j is 3, and k is 3. In some embodiments, i is 0, j is 3, and k is 4.
  • i 0, j is 4, and k is 0. In some embodiments, i is 0, j is 4, and k is 1. In some embodiments, i is 0, j is 4, and k is 2. In some embodiments, i is 0, j is 4, and k is 3. In some embodiments, i is 0, j is 4, and k is 4. In some embodiments, i is 1, j is 0, and k is 0. In some embodiments, i is 1, j is 1, and k is 0. In some embodiments, i is 1, j is 1, and k is 1. In some embodiments, i is 1, j is 1, and k is 2. In some embodiments, i is 1, j is 1, and k is 3.
  • i 1, j is 1, and k is 4. In some embodiments, i is 2, j is 1, and k is 1. In some embodiments, i is 2, j is 1, and k is 2. In some embodiments, i is 2, j is 1, and k is 3. In some embodiments, i is 2, j is 1, and k is 4. In some embodiments, i is 3, j is 1, and k is 1. In some embodiments, i is 3, j is 1, and k is 2. In some embodiments, i is 3, j is 1, and k is 3. In some embodiments, i is 3, j is 1, and k is 4. In some embodiments, i is 4, j is 1, and k is 1.
  • i 4, j is 1, and k is 2. In some embodiments, i is 4, j is 1, and k is 3. In some embodiments, i is 4, j is 1, and k is 4. In some embodiments, i is 1, j is 2, and k is 0. In some embodiments, i is 1, j is 2, and k is 1. In some embodiments, i is 1, j is 2, and k is 2.
  • i is 1, j is 2, and k is 3. In some embodiments, i is 1, j is 2, and k is 4.
  • i is 1, j is 3, and k is 0. In some embodiments, i is 1, j is 3, and k is 1.
  • i 1, j is 3, and k is 2. In some embodiments, i is 1, j is 3, and k is 3.
  • i 1, j is 3, and k is 4. In some embodiments, i is 2, j is 4, and k is 0.
  • i is 2, j is 4, and k is 1. In some embodiments, i is 2, j is 4, and k is 2.
  • i is 2, j is 4, and k is 3. In some embodiments, i is 2, j is 4, and k is 4.
  • i is 3, j is 2, and k is 0. In some embodiments, i is 3, j is 2, and k is 1.
  • i is 3, j is 2, and k is 2. In some embodiments, i is 3, j is 2, and k is 3.
  • i is 3, j is 2, and k is 4. In some embodiments, i is 4, j is 3, and k is 0.
  • i is 4, j is 3, and k is 1. In some embodiments, i is 4, j is 3, and k is 2.
  • i is 4, j is 3, and k is 3. In some embodiments, i is 4, j is 3, and k is 4.
  • i is 4, j is 4, and k is 0. In some embodiments, i is 4, j is 4, and k is 1.
  • i is 4, j is 4, and k is 2. In some embodiments, i is 4, j is 4, and k is 3.
  • i is 4, j is 4, and k is 4.
  • j is 0 and k is 0. In some embodiments, j is 0 and k is 1. In some embodiments, j is 0 and k is 2. In some embodiments, j is 0 and k is 3. In some embodiments, j is 0 and k is 4. In some embodiments, j is 1 and k is 0. In some embodiments, j is 1 and k is 1. In some embodiments, j is 1 and k is 2. In some embodiments, j is 1 and k is 3. In some embodiments, j is 1 and k is 4. In some embodiments, j is 2 and k is 0. In some embodiments, j is 2 and k is 1. In some embodiments, j is 2 and k is 2.
  • j is 2 and k is 3. In some embodiments, j is 2 and k is 4. In some embodiments, j is 3 and k is 0. In some embodiments, j is 3 and k is 1. In some embodiments, j is 3 and k is 2. In some embodiments, j is 3 and k is 3. In some embodiments, j is 3 and k is 4. In some embodiments, j is 4 and k is 0. In some embodiments, j is 4 and k is 1. In some embodiments, j is 4 and k is 2. In some embodiments, j is 4 and k is 3. In some embodiments, j is 4 and k is 4.
  • m, x, y, and z are independently integer 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • m, x, and y are independently integer from 1 to 15 (e.g., from 1 to 14, from 1 to 13, from 1 to 12, from 1 to 11, from 1 to 10, from 1 to 9, from 1 to 8, from 1 to 7, from 1 to 6, from 1 to 5, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 15, from 2 to 14, from 2 to 13, from 2 to 12, from 2 to 11, from 2 to 10, from 2 to 9, from 2 to 8, from 2 to 7, from 2 to 6, from 2 to 5, from 2 to 4, from 2 to 3, from 3 to 15, from 3 to 14, from 3 to 13, from 3 to 12, from 3 to 11, from 3 to 10, from 3 to 9, from 3 to 8, from 3 to 7, from 3 to 6, from 3 to 5, from 3 to 4, from 4 to 15, from 4 to 14, from 4 to 13, from 4 to 12, from 4 to 11, from 4 to 10, from 4 to 9, from 4 to 8, from 4 to 7, from 4 to 6,
  • compositions including a compound of Formula I, II, III, IV, V, VI, or any combination thereof and an active agent.
  • the compositions can further include an excipient of some sort may be useful in a variety of medical and non- medical applications.
  • pharmaceutical compositions described herein may be useful in the delivery of an effective amount of an agent to a subject in need thereof.
  • Compositions described herein may be useful for non-medical applications, e.g., such as an emulsion or emulsifier, useful, for example, as a food component, for extinguishing fires, for disinfecting surfaces, for oil cleanup, etc.
  • the composition can be a lipid nanoparticle dispersion, a liposomal formulation, a lipid emulsion, or any combination thereof including a compound of Formula I, II, III, IV, V, VI, or any combination thereof.
  • the disclosure provides a composition including: a lipid nanoparticle, including a compound of Formula I, II, III, IV, V, VI, or any combination thereof; and an active agent.
  • the composition can include an agent, as described herein.
  • the agent is any chemical compound to be administered to a subject may be delivered using the particles or nanoparticles described herein.
  • the agent may be an organic molecule (e.g., a therapeutic agent, a drug), inorganic molecule, small molecule, organometallic compound, metal, nucleic acid, protein, amino acid, peptide, polypeptide, polynucleotide, targeting agent, isotopically labeled organic or inorganic molecule, vaccine, immunological agent, or an agent useful in bioprocessing.
  • the agent is a polynucleotide.
  • the agent includes an mRNA encoding at least one antigenic polypeptide or an immunogenic fragment thereof capable of inducing an immune response to the antigenic polypeptide.
  • the mRNA encoding at least one antigenic polypeptide or an immunogenic fragment thereof capable of inducing an immune response to the antigenic polypeptide is encapsulated by the nanoparticle.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a nanoparticle comprising a compound of Formula I, II, III, IV, V, VI, or any combination thereof; and an mRNA encoding at least one antigenic polypeptide or an immunogenic fragment thereof capable of inducing an immune response to the antigenic polypeptide.
  • lipid nanoparticles including 20% to 80% of a compound described herein (e.g., a compound of Formula I, II, III, IV, V, VI, or any combination thereof); greater than 0 % to 5 % polyethylene glycol- lipid; greater than 0 % to 40 % helper lipids; 0 % to 80 % sterol; and an active agent encapsulated in the nanoparticle.
  • the lipid nanoparticle can further include a cationic lipid.
  • compositions including an effective amount of a lipid nanoparticle described herein and a carrier.
  • the carrier can be a pharmaceutically acceptable carrier.
  • nanoparticle including: a compound of Formula I, II, III, IV, V, VI, or any combination thereof; and optionally a helper lipid; a polyethylene glycollipid; a sterol, or any combination thereof; and an active agent encapsulated in the nanoparticle.
  • nanoparticle including: a compound of Formula I, II, III, IV, V, VI, or any combination thereof; and a helper lipid; a polyethylene glycol-lipid; and/or a sterol; and an active agent encapsulated in the nanoparticle.
  • nanoparticle including: a compound of Formula I, II, III, IV, V, VI, or any combination thereof; a helper lipid; a polyethylene glycol-lipid; and a sterol; and an active agent encapsulated in the nanoparticle.
  • nanoparticle including: a compound of Formula I; and a helper lipid; a polyethylene glycol-lipid; and/or a sterol; and an active agent encapsulated in the nanoparticle.
  • nanoparticle including: a compound of Formula II; and a helper lipid; a polyethylene glycol-lipid; and/or a sterol; and an active agent encapsulated in the nanoparticle.
  • nanoparticle including: a compound of Formula III; and a helper lipid; a polyethylene glycol-lipid; and/or a sterol; and an active agent encapsulated in the nanoparticle.
  • the disclosure provides a nanoparticle comprising: a compound of Formula IV; and a helper lipid; a polyethylene glycol-lipid; and/or a sterol; and an active agent encapsulated in the nanoparticle.
  • the nanoparticle comprises a compound of Formula I, II, III, IV, V, VI, or any combination thereof in a molar ratio of from 20% to 80%; and an active agent encapsulated in the nanoparticle.
  • the nanoparticle comprises a helper lipid.
  • the helper lipid can be a non-cationic lipid.
  • the non-cationic lipid can include, but is not limited to, l,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1- palmitoyl-2-olcoyl-.77-glyccro-3-phosphoclhanolaminc (POPE), l,2-distearoyl-OT-glycero-3- phosphocholine (DSPC), l-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (SOPE), 1,2- dipalmitoyl-sn-glycero-3- phosphocholine (DPPC), l,2-dioleyl-sn-glycero-3- phosphotidylcholine (DOPC), l,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DOPE),
  • the non-cationic lipid is 1 ,2-dioleoyl- OT-glycero-3-phosphoethanolamine (DOPE). In one embodiment, the non-cationic lipid is 1- palmitoyl-2-oleoyl- , n-glycero-3-phosphoethanolamine (POPE), In one embodiment, the noncationic lipid is 1 .2-distearoyl-.sn-glyccro-3 -phosphocholine (DSPC).
  • the non-cationic lipid is l-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (SOPE). While several non-cationic lipids are described here, additional non-cationic lipids can be used in combination with the compounds disclosed herein.
  • SOPE l-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine
  • the helper lipid can be present in a molar ratio of at least 0%, (e.g., at least 5%, at least 10%, at least 20%, at least 30%, or at least 40%). In some embodiments, the helper lipid can be present in a molar ratio of 40% or less, (e.g., 30% or less, 20% or less, 10% or less, 5% or less, 1% or less, or 0.5% or less).
  • the helper lipid can be present in a molar ratio ranging from any of the minimum values described above to any of the maximum values described above.
  • the helper lipid can be present in a molar ratio of from 0% to 40% (e.g., from greater than 0% to 30%, from greater than 0% to 20%, from greater than 0% to 10%, from greater than 0% to 5%, from greater than 0% to 1%, from greater than 0% to 0.5%, from 1% to 30%, from 1% to 20%, from 1% to 10%, from 1% to 5%, from 5% to 30%, from 5% to 20%, from 5% to 10%, from 10% to 30%, from 10% to 20%, from 20% to 30%, from 20% to 40%, or from 30% to 40%).
  • the nanoparticle includes a polyethylene glycol-lipid (PEG- lipid).
  • PEG-lipid is incorporated to form a hydrophilic outer layer and stabilize the particles.
  • Nonlimiting examples of polyethylene glycol-lipids include PEG-modified lipids such as PEG- modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG- modified dialkylamines, PEG-modified diacylglycerols, and PEG-modified dialkylglycerols.
  • Representative polyethylene glycol-lipids include DMG-PEG, DLPE-PEGs, DMPE-PEGs, DPPC-PEGs, and DSPE-PEGs.
  • the polyethylene glycollipid is 1,2-dimyristoyl-sn-glycerol, methoxypolyethylene glycol (DMG-PEG). In one embodiment, the polyethylene glycol-lipid is 1,2-dimyristoyl-sn-glycerol, methoxypolyethylene glycol-2000 (DMG-PEG2000). DMG-PEGXXXX means 1,2- dimyristoyl-sn-glycerol, methoxypolyethylene glycol-XXXX, wherein XXX signifies the molecular weight of the polyethylene glycol moiety, e.g. DMG-PEG2000 or DMG-PEG5000.
  • the lipid nanoparticle can further include a cationic lipid.
  • Suitable cationic lipid can include, but not limited to, l,2-dioleoyl-3-trimethylammonium propane (DOTAP), l,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), dimethyldimyristylammonium, N-hexadecyl-N,N-dimethylhexadecan- 1 -aminium, N-(2- hydroxyethyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-l-aminium (DORI), N-(4- carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-l-aminium (DOBAQ).
  • DOTAP l,2-dioleoyl-3-trimethylammonium propane
  • DOTMA l,2-di
  • the polyethylene glycol-lipid can be present in a molar ratio of at least 0%, (e.g., at least 0.25%, at least 0.5%, at least 0.75%, at least 1%, at least 1.5%, at least 2%, at least 3%, at least 4%, or at least 5%). In some embodiments, the polyethylene glycol-lipid can be present in a molar ratio of 5% or less, (e.g., 4% or less, 3% or less, 2% or less, 1% or less, or 0.5% or less).
  • the polyethylene glycol-lipid can be present in a molar ratio ranging from any of the minimum values described above to any of the maximum values described above.
  • the polyethylene glycol-lipid can be present in a molar ratio of from 0% to 5% (e.g., from greater than 0% to 4%, from greater than 0% to 3%, from greater than 0% to 2%, from greater than 0% to 1%, from greater than 0% to 0.5%, from 1% to 5%, from 1% to 4%, from 1% to 3%, from 1% to 2%, from 2% to 5%, 2% to 4%, 2% to 3%, from 3% to 5%, from 3% to 4%, or 4% to 5%).
  • the polyethylene glycol-lipid in a molar ratio of 0.75%.
  • the nanoparticle includes a sterol.
  • Sterols are well known to those skilled in the art and generally refers to those compounds having a perhydrocyclopentanophenanthrene ring system and having one or more OH substituents. Examples of sterols include, but are not limited to, cholesterol, campesterol, ergosterol, sitosterol, and the like.
  • the sterol is selected from a cholesterol-based lipid.
  • the one or more cholesterol-based lipids are selected from cholesterol, PEGylated cholesterol, DC-Choi (N,N-dimethyl-N-ethylcarboxamidocholesterol), l,4-bis(3- N-oleylamino-propyl)piperazine, or combinations thereof.
  • the sterol can be used to tune the particle permeability and fluidity base on its function in cell membranes.
  • the sterol is cholesterol.
  • the sterol can be present in a molar ratio ranging from any of the minimum values described above to any of the maximum values described above.
  • the sterol can be present in a molar ratio of from 0% to 80%, (e.g., from greater than 0% to 70%, from greater than 0% to 60%, from greater than 0% to 50% from greater than 0% to 40%, from greater than 0% to 30%, from greater than 0% to 20%, from greater than 0% to 10%, from greater than 0% to 5%, from greater than 0% to 1%, from 5% to 70%, from 5% to 60%, from 5% to 50% from 5% to 40%, from 5% to 30%, from 5% to 20%, from 5% to 10%, from 10% to 70%, from 10% to 60%, from 10% to 50% from 10% to 40%, from 10% to 30%, from 10% to 20%, from 20% to 70%, from 20% to 60%, from 20% to 50%, from 20% to 40%, from 20% to 30%, from 30% to 70%, from 30% to 60%, from 30% to 50%, from 30% to 40%, from 0%
  • the nanoparticle can include from 40% to 60% of a compound described herein; from 1% to 2% polyethylene glycol-lipid; from 8% to 12% helper lipids; from 35% to 40% sterol; and an active agent encapsulated in the nanoparticle.
  • nanoparticles including 50% of a compound described herein; 1.5% polyethylene glycol-lipid; 10% helper lipids (e.g., DSPC); 38.5% sterol (e.g., cholesterol); and an active agent encapsulated in the nanoparticle.
  • helper lipids e.g., DSPC
  • sterol e.g., cholesterol
  • the disclosure provides a nanoparticle comprising: a compound of Formula I, II, III, IV, V, VI, or any combination thereof; and an active agent encapsulated in the nanoparticle.
  • nanoparticles including: a compound of Formula I, II, III, IV, V, VI, or any combination thereof;
  • Beta-sitosterol and an active agent encapsulated in the nanoparticle.
  • the disclosure provides a nanoparticle comprising: a compound of Formula I, II, III, IV, V, VI, or any combination thereof; l-palmitoyl-2-oleoyl-5n-glycero-3-phosphoethanolamine (POPE);
  • POPE l-palmitoyl-2-oleoyl-5n-glycero-3-phosphoethanolamine
  • DMG-PEG2000 methoxypolyethylene glycol
  • the disclosure provides a nanoparticle comprising: a compound of Formula I, II, III, IV, V, VI, or any combination thereof; 1.2-distearoyl-sn-glycero-3-phosphocholine (DSPC);
  • Cholesterol Cholesterol
  • an active agent encapsulated in the nanoparticle.
  • the disclosure provides a nanoparticle comprising: a compound of Formula I, II, III, IV, V, VI, or any combination thereof;
  • DSPC 1.2-distearoyl-sn-glycero-3-phosphocholine
  • the disclosure provides a nanoparticle comprising: a compound of Formula I, II, III, IV, V, VI, or any combination thereof;
  • DSPC 1.2-distearoyl-sn-glycero-3-phosphocholine
  • Beta-sitosterol and an active agent encapsulated in the nanoparticle.
  • the disclosure provides a nanoparticle comprising: a compound of Formula I, II, III, IV, V, VI, or any combination thereof;
  • DSPC 1.2-distearoyl-sn-glycero-3-phosphocholine
  • Beta-sitosterol and an active agent encapsulated in the nanoparticle.
  • the nanoparticle can further include an active agent. In one embodiment, the nanoparticle can further include a therapeutic agent. In one embodiment, the nanoparticle can further include a diagnostic agent. In one embodiment, the nanoparticle can further include a prophylactic agent.
  • an “active agent” refers to therapeutic agents, diagnostic agents, or prophylactic agents. As discussed herein, the therapeutic agents can be released from the disclosed compounds, compositions, and systems in a biologically active form.
  • therapeutic agents refers to one or more therapeutic agents, active ingredients, or substances that can be used to treat a medical condition.
  • Therapeutic agent includes any synthetic or naturally occurring biologically active compound or composition of matter which, when administered to an organism (human or nonhuman animal), induces a desired pharmacologic, immunogenic, and/or physiologic effect by local and/or systemic action.
  • the term therefore encompasses those compounds or chemicals traditionally regarded as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, hormones, nucleic acids, gene constructs and the like.
  • therapeutic agents are described in well-known literature references such as the Merck Index (14th edition), the Physicians' Desk Reference (64th edition), and The Pharmacological Basis of Therapeutics (12th edition), and they include, without limitation, medicaments; vitamins and minerals such as essential amino acids, calcium, iron, potassium, zinc, vitamin B12, and the like; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment.
  • the term “therapeutic agent” includes compounds or compositions for use in all of the major therapeutic areas including, but not limited to, adjuvants; an antimicrobial agents (including antibiotics, antiviral agents, antiparasitic, and anti-fungal agents), anti-inflammatory agents (including steroids and non-steroidal antiinflammatory agents), anti-coagulant agents, ophthalmic agents, gastrointestinal drugs, antiplatelet agents, and antiseptic agents, steroidal agent, anti-neoplastic agent, anti-cancer agent, antigen, antibody (e.g., cetuximab, anti-CD24 antibody, panitumumab and bevacizumab), birth control agent, progestational agent, anti-cholinergic, nutritional agent, analgesics and analgesic combinations such as acetaminophen, acetylsalicylic acid, and the like; anesthetics such as lidocaine, xylocaine, and the like, anorexics such as dexadrine, phend
  • antibiotics include amikacin, amoxicillin, ampicillin, atovaquone, azithromycin, aztreonam, bacitracin, carbenicillin, cefadroxil, cefazolin, cefdinir, cefditoren, cefepime, cefiderocol, cefoperazone, cefotetan, cefoxitin, cefotaxime, cefpodoxime, cefprozil, ceftaroline, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, chloramphenicol, colistimethate, cefuroxime, cephalexin, cephradine, cilastatin, cinoxacin, ciprofloxacin, clarithromycin, clindamycin, dalbavancin, dalfopristin, daptomycin, demeclocycline, dicloxacillin, doripenem,
  • antiviral agents include, but are not limited to, abacavir, acyclovir, adefovir, amantadine, amprenavir, atazanavir, balavir, baloxavir marboxil, boceprevir, cidofovir, cobicistat, daclatasvir, darunavir, delavirdine, didanosine, docasanol, dolutegravir, doravirine, ecoliever, edoxudine, efavirenz, elvitegravir, emtricitabine, enfuvirtide, entecavir, etravirine, famciclovir, fomivirsen, fosamprenavir, forscarnet, fosnonet, famciclovir, favipravir, fomivirsen, foscavir, ganciclovir, ibacitabine, idoxuridine, indinavir, in
  • anticoagulant agents include, but are not limited to, heparin, warfarin, rivaroxaban, dabigatran, apixaban, edoxaban, enoxaparin, and fondaparinux.
  • antiplatelet agents include, but are not limited to, clopidogrel, ticagrelor, prasugrel, dipyridamole, dipyridamole/aspirin, ticlopidine, and eptifibatide.
  • antifungal agents include, but are not limited to, voriconazole, itraconazole, posaconazole, fluconazole, ketoconazole, clotrimazole, isavuconazonium, miconazole, caspofungin, anidulafungin, micafungin, griseofulvin, terbinafine, flucytosine, terbinafine, nystatin, and amphotericin b.
  • steroidal anti-inflammatory agents include, but are not limited to, hydrocortisone, dexamethasone, prednisolone, prednisone, triamcinolone, methylprednisolone, budesonide, betamethasone, cortisone, and deflazacort.
  • non-steroidal anti-inflammatory drugs include ibuprofen, naproxen, ketoprofen, tolmetin, etodolac, fenoprofen, flurbiprofen, diclofenac, piroxicam, indomethacin, sulindax, meloxicam, nabumetone, oxaprozin, mefenamic acid, and diflunisal.
  • active agents include chloroquine, hydrochloroquine, Pyridoxal phosphate, Vitamin D, and Vitamin C.
  • anticytokine or immunomodulatory agents include tocilizumab, sarilumab, bevacizumab, fingolimod, imiquimod, and eculizumab.
  • Immunotherapeutic agent can include but are not limited to an anti-CD40 antibody, an anti-PDLl antibody (e.g., atezolizumab, durvalumab, or avelumab), an anti-PDl antibody, an anti-CTLA4 antibody, programmed death protein 1 (PD-1) inhibitor or programmed death protein ligand 1 or 2 inhibitor include, (e.g., nivolumab (BMS), pembrolizumab (Merck), pidilizumab (CureTech/Teva), AMP-244 (Amplimmune/GSK), BMS-936559 (BMS), and MEDI4736 (Roche/Genentech)),or a combination thereof.
  • an anti-CD40 antibody e.g., an anti-PDLl antibody (e.g., atezolizumab, durvalumab, or avelumab), an anti-PDl antibody, an anti-CTLA4 antibody, programmed death protein 1 (PD-1) inhibitor or programmed death
  • contraceptives include, but are not limited to, progestins, estrogens, or any combination thereof.
  • suitable progestins include, but are not limited to, natural and synthetic compounds having progestational activity, such as, for example, progesterone, chlormadinone acetate, norethindrone, cyproterone acetate, norethindrone acetate, desogestrel, levonorgestrel, drospirenone, trimegestone, norgestrel, norgestimate, norelgestromin, etonogestrel, gestodene, and other natural and/or synthetic gestagens.
  • suitable estrogens include, but are not limited to, natural and synthetic compounds having estrogenic activity, such as, for example, estradiol (17P-estradiol), 17a- estradiol, estriol, estrone, and their esters, such as the acetate, sulfate, valerate or benzoate esters of these compounds, including, for example, estradiol 17p-cypionate, estradiol 17- propionate, estradiol 3-benzoate, and piperazine estrone sulfate; ethinyl estradiol; conjugated estrogens (natural and synthetic); mestranol; agonistic anti-estrogens; and selective estrogen receptor modulators.
  • estradiol 17P-estradiol
  • 17a- estradiol estriol
  • estrone and their esters
  • esters such as the acetate, sulfate, valerate or benzoate esters of these compounds, including, for example, estradiol 17p-cypion
  • contraceptives include gonodotropin releasing hormone (GnRh) or anologs thereof such as deslorelin, avorelin, leuprolide, triptorelin, nafarelin, goserelin, buserelin, and fertirelin.
  • GnRh gonodotropin releasing hormone
  • steroid refers to compounds belonging to or related to the following illustrative families of compounds: corticosteroids, mineralico steroids, and sex steroids (including, for example, potentially androgenic or estrogenic or anti- androgenic and antiestrogenic molecules).
  • the therapeutic agent may comprise a steroid.
  • Exemplary cancer drugs or anti-cancer agents can include, but are not limited to, antimetabolite anti- cancer agents and antimitotic anti-cancer agents, and combinations thereof.
  • Various antimetabolite and antimitotic anti-cancer agents, including single such agents or combinations of such agents, may be employed in the methods and compositions described herein.
  • Antimetabolic anti-cancer agents typically structurally resemble natural metabolites, which are involved in normal metabolic processes of cancer cells such as the synthesis of nucleic acids and proteins.
  • the antimetabolites differ enough from the natural metabolites such that they interfere with the metabolic processes of cancer cells.
  • antimetabolites are mistaken for the metabolites they resemble, and are processed by the cell in a manner analogous to the normal compounds.
  • the presence of the “decoy” metabolites prevents the cells from carrying out vital functions and the cells are unable to grow and survive.
  • antimetabolites may exert cytotoxic activity by substituting these fraudulent nucleotides into cellular DNA, thereby disrupting cellular division, or by inhibition of critical cellular enzymes, which prevents replication of DNA.
  • the antimetabolite anti-cancer agent is a nucleotide or a nucleotide analog.
  • the antimetabolite agent may comprise purine (e.g., guanine or adenosine) or analogs thereof, or pyrimidine (cytidine or thymidine) or analogs thereof, with or without an attached sugar moiety.
  • Suitable antimetabolite anti-cancer agents for use in the present disclosure may be generally classified according to the metabolic process they affect, and can include, but are not limited to, analogues and derivatives of folic acid, pyrimidines, purines, and cytidine.
  • the antimetabolite agent(s) is selected from the group consisting of cytidine analogs, folic acid analogs, purine analogs, pyrimidine analogs, and combinations thereof.
  • the antimetabolite agent is a cytidine analog.
  • the cytidine analog may be selected from the group consisting of cytarabine (cytosine arabinodside), azacitidine (5-azacytidine), and salts, analogs, and derivatives thereof.
  • the antimetabolite agent is a folic acid analog.
  • Folic acid analogs or antifolates generally function by inhibiting dihydrofolate reductase (DHFR), an enzyme involved in the formation of nucleotides; when this enzyme is blocked, nucleotides are not formed, disrupting DNA replication and cell division.
  • DHFR dihydrofolate reductase
  • the folic acid analog may be selected from the group consisting of denopterin, methotrexate (amethopterin), pemetrexed, pteropterin, raltitrexed, trimetrexate, and salts, analogs, and derivatives thereof.
  • the antimetabolite agent is a purine analog.
  • Purine-based antimetabolite agents function by inhibiting DNA synthesis, for example, by interfering with the production of purine containing nucleotides, adenine and guanine which halts DNA synthesis and thereby cell division.
  • Purine analogs can also be incorporated into the DNA molecule itself during DNA synthesis, which can interfere with cell division.
  • the purine analog may be selected from the group consisting of acyclovir, allopurinol, 2-aminoadenosine, arabinosyl adenine (ara-A), azacitidine, azathiprine, 8-aza-adenosine, 8-fluoro-adenosine, 8-methoxy-adenosine, 8-oxo-adenosine, cladribine, deoxycoformycin, fludarabine, gancylovir, 8-aza-guanosine, 8-fluoro-guanosine, 8- methoxyguanosine, 8-oxo-guanosine, guanosine diphosphate, guanosine dipho sphate-beta- L-2- aminofucose, guanosine diphosphate-D-arabinose, guanosine diphosphate-2- fluorofucose, guanosine
  • the antimetabolite agent is a pyrimidine analog. Similar to the purine analogs discussed above, pyrimidine-based antimetabolite agents block the synthesis of pyrimidine-containing nucleotides (cytosine and thymine in DNA; cytosine and uracil in RNA). By acting as “decoys,” the pyrimidine-based compounds can prevent the production of nucleotides, and/or can be incorporated into a growing DNA chain and lead to its termination.
  • the pyrimidine analog may be selected from the group consisting of ancitabine, azacitidine, 6-azauridine, bromouracil (e.g., 5 -bromouracil), capecitabine, carmofur, chlorouracil (e.g.
  • 5-chlorouracil 5-chlorouracil
  • cytarabine cytosine arabinoside
  • cytosine dideoxyuridine, 3 '-azido-3 '-deoxy thymidine, 3'- dideoxycytidin-2'-ene, 3'-deoxy-3'-deoxythymidin-2'-ene, dihydrouracil, doxifluridine, enocitabine, floxuridine, 5-fluorocytosine, 2-fluorodeoxycytidine, 3-fluoro-3'- deoxythymidine, fluorouracil (e.g., 5-fluorouracil (also known as 5-FU), gemcitabine, 5- methylcytosine, 5- propynylcytosine, 5-propynylthymine, 5-propynyluracil, thymine, uracil, uridine, and salts, analogs, and derivatives thereof.
  • the pyrimidine analog is
  • the antimetabolite agent is selected from the group consisting of 5- fluorouracil, capecitabine, 6-mercaptopurine, methotrexate, gemcitabine, cytarabine, fludarabine, pemetrexed, and salts, analogs, derivatives, and combinations thereof.
  • the antimetabolite agent is selected from the group consisting of capecitabine, 6- mercaptopurine, methotrexate, gemcitabine, cytarabine, fludarabine, pemetrexed, and salts, analogs, derivatives, and combinations thereof.
  • the antimetabolite agent is other than 5-fluorouracil.
  • the antimetabolite agent is gemcitabine or a salt or thereof (e.g., gemcitabine HC1 (Gemzar®)).
  • antimetabolite anti-cancer agents may be selected from, but are not limited to, the group consisting of acanthifolic acid, aminothiadiazole, brequinar sodium, Ciba-Geigy CGP-30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, Wellcome EHNA, Merck & Co.
  • EX-015 benzrabine, fludarabine phosphate, N-(2'-furanidyl)-5-fluorouracil, Daiichi Seiyaku FO-152, 5-FU-fibrinogen, isopropyl pyrrolizine, Lilly LY-188011; Lilly LY-264618, methobenzaprim, Wellcome MZPES, norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC- 612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC-788, tiazofurin, Erbamont TIF, tyrosine kinase inhibitors, Taiho UFT and uricytin, among others.
  • the antimitotic anti-cancer agent is a microtubule inhibitor or a microtubule stabilizer.
  • microtubule stabilizers such as taxanes and epothilones, bind to the interior surface of the beta-microtubule chain and enhance microtubule assembly by promoting the nucleation and elongation phases of the polymerization reaction and by reducing the critical tubulin subunit concentration required for microtubules to assemble.
  • the microtubule stabilizers such as taxanes, decrease the lag time and dramatically shift the dynamic equilibrium between tubulin dimers and microtubule polymers towards polymerization.
  • the microtubule stabilizer is a taxane or an epothilone.
  • the microtubule inhibitor is a vinca alkaloid.
  • the anti-cancer agent may comprise a taxane or derivative or analog thereof.
  • the taxane may be a naturally derived compound or a related form, or may be a chemically synthesized compound or a derivative thereof, with antineoplastic properties.
  • the taxanes are a family of terpenes, including, but not limited to paclitaxel (Taxol®) and docetaxel (Taxotere®), which are derived primarily from the Pacific yew tree, Taxus brevifolia, and which have activity against certain tumors, particularly breast and ovarian tumors.
  • the taxane is docetaxel or paclitaxel.
  • Paclitaxel is a preferred taxane and is considered an antimitotic agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
  • Taxane derivatives include, but are not limited to, galactose and mannose derivatives described in International Patent Application No. WO 99/18113; piperazino and other derivatives described in WO 99/14209; taxane derivatives described in WO 99/09021, WO 98/22451, and U.S. Pat. No. 5,869,680; 6-thio derivatives described in WO 98/28288; sulfenamide derivatives described in U.S. Pat. No. 5,821,263; deoxygenated paclitaxel compounds such as those described in U.S. Pat. No.
  • the taxane may also be a taxane conjugate such as, for example, paclitaxel-PEG, paclitaxel-dextran, paclitaxel-xylose, docetaxel-PEG, docetaxel- dextran, docetaxel-xylose, and the like. Other derivatives are mentioned in “Synthesis and Anticancer Activity of Taxol Derivatives,” D. G.
  • the antimitotic anti-cancer agent can be a microtubule inhibitor; in one preferred aspect, the microtubule inhibitor is a vinca alkaloid.
  • the vinca alkaloids are mitotic spindle poisons.
  • the vinca alkaloid agents act during mitosis when chromosomes are split and begin to migrate along the tubules of the mitosis spindle towards one of its poles, prior to cell separation. Under the action of these spindle poisons, the spindle becomes disorganized by the dispersion of chromosomes during mitosis, affecting cellular reproduction.
  • the vinca alkaloid is selected from the group consisting of vinblastine, vincristine, vindesine, vinorelbine, and salts, analogs, and derivatives thereof.
  • the antimitotic anti-cancer agent can also be an epothilone.
  • members of the epothilone class of compounds stabilize microtubule function according to mechanisms similar to those of the taxanes.
  • Epothilones can also cause cell cycle arrest at the G2-M transition phase, leading to cytotoxicity and eventually apoptosis.
  • Suitable epithiolones include epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, and epothilone F, and salts, analogs, and derivatives thereof.
  • One particular epothilone analog is an epothilone B analog, ixabepilone (IxempraTM).
  • the antimitotic anti-cancer agent is selected from the group consisting of taxanes, epothilones, vinca alkaloids, and salts and combinations thereof.
  • the antimitotic agent is a taxane. More preferably in this aspect the antimitotic agent is paclitaxel or docetaxel, still more preferably paclitaxel.
  • the antimitotic agent is an epothilone (e.g., an epothilone B analog).
  • the antimitotic agent is a vinca alkaloid.
  • cancer drugs examples include, but are not limited to: thalidomide; platinum coordination complexes such as cisplatin (cis-DDP), oxaliplatin and carboplatin; anthracenediones such as mitoxantrone; substituted ureas such as hydroxyurea; methylhydrazine derivatives such as procarbazine (N- methylhydrazine, MIH); adrenocortical suppressants such as mitotane (o,p'-DDD) and aminoglutethimide; RXR agonists such as bexarotene; and tyrosine kinase inhibitors such as sunitinib and imatinib.
  • platinum coordination complexes such as cisplatin (cis-DDP), oxaliplatin and carboplatin
  • anthracenediones such as mitoxantrone
  • substituted ureas such as hydroxyurea
  • methylhydrazine derivatives
  • Examples of additional cancer drugs include alkylating agents, antimetabolites, natural products, hormones and antagonists, and miscellaneous agents. Alternate names are indicated in parentheses.
  • alkylating agents include nitrogen mustards such as mechlorethamine, cyclophosphainide, ifosfamide, melphalan sarcolysin) and chlorambucil; ethylenimines and methylmelamines such as hexamethylmelamine and thiotepa; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine (BCNU), semustine (methyl- CCNU), lomustine (CCNU) and streptozocin (streptozotocin); DNA synthesis antagonists such as estramustine phosphate; and triazines such as dacarbazine (DTIC, dimethyl- triazenoimidazolecarboxamide) and temozolomide.
  • DTIC dimethyl- tri
  • antimetabolites include folic acid analogs such as methotrexate (amethopterin); pyrimidine analogs such as fluorouracin (5- fluorouracil, 5-FU, SFU), floxuridine (fluorodeoxyuridine, FUdR), cytarabine (cytosine arabinoside) and gemcitabine; purine analogs such as mercaptopurine (6-mercaptopurine, 6- MP), thioguanine (6-thioguanine, TG) and pentostatin (2'-deoxycoformycin, deoxycoformycin), cladribine and fludarabine; and topoisomerase inhibitors such as amsacrine.
  • folic acid analogs such as methotrexate (amethopterin)
  • pyrimidine analogs such as fluorouracin (5- fluorouracil, 5-FU, SFU), floxuridine (fluorodeoxyuridine, FUdR), cytarabine (cytos
  • Examples of natural products include vinca alkaloids such as vinblastine (VLB) and vincristine; taxanes such as paclitaxel, protein bound paclitaxel (Abraxane) and docetaxel (Taxotere); epipodophyllotoxins such as etoposide and teniposide; camptothecins such as topotecan and irinotecan; antibiotics such as dactinomycin (actinomycin D), daunorubicin (daunomycin, rubidomycin), doxorubicin, histrelin, bleomycin, mitomycin (mitomycin C), idarubicin, epirubicin; enzymes such as L-asparaginase; and biological response modifiers such as interferon alpha and interlelukin 2.
  • VLB vinblastine
  • vincristine taxanes
  • paclitaxel protein bound paclitaxel
  • Abraxane protein bound paclitaxel
  • hormones and antagonists include luteinising releasing hormone agonists such as buserelin; adrenocorticosteroids such as prednisone and related preparations; progestins such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogens such as diethyl stilbestrol and ethinyl estradiol and related preparations; estrogen antagonists such as tamoxifen and anastrozole; androgens such as testosterone propionate and fluoxymesterone and related preparations; androgen antagonists such as flutamide and bicalutamide; and gonadotropinreleasing hormone analogs such as leuprolide. Alternate names and trade-names of these and additional examples of cancer drugs, and their methods of use including dosing and administration regimens, will be known to a person versed in the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes d'administration d'agents thérapeutiques, diagnostiques ou prophylactiques (par exemple, un acide nucléique).
PCT/US2025/015066 2024-02-07 2025-02-07 Lipides et nanoparticules lipidiques les comprenant Pending WO2025171300A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463551031P 2024-02-07 2024-02-07
US63/551,031 2024-02-07

Publications (1)

Publication Number Publication Date
WO2025171300A1 true WO2025171300A1 (fr) 2025-08-14

Family

ID=96700622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/015066 Pending WO2025171300A1 (fr) 2024-02-07 2025-02-07 Lipides et nanoparticules lipidiques les comprenant

Country Status (1)

Country Link
WO (1) WO2025171300A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050195943A1 (en) * 2002-07-31 2005-09-08 Fuji Photo Film Co., Ltd. Method of forming subtraction images
US20110200582A1 (en) * 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011153493A2 (fr) * 2010-06-03 2011-12-08 Alnylam Pharmaceuticals, Inc. Lipides biodégradables pour l'administration de principes actifs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050195943A1 (en) * 2002-07-31 2005-09-08 Fuji Photo Film Co., Ltd. Method of forming subtraction images
US20110200582A1 (en) * 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011153493A2 (fr) * 2010-06-03 2011-12-08 Alnylam Pharmaceuticals, Inc. Lipides biodégradables pour l'administration de principes actifs

Similar Documents

Publication Publication Date Title
US20250092083A1 (en) Sterol based ionizable lipids and lipid nanoparticles comprising the same
US10828373B2 (en) Bioorthogonal compositions
JP2020180153A (ja) 真菌感染症の治療方法
JP7470988B2 (ja) 生物応答性ヒドロゲルマトリックス及び使用方法
CA2881440A1 (fr) Vehicule d'administration de medicament comprenant des conjugues entre des acides polyamines de ciblage et des acides gras
WO2023192916A2 (fr) Arn comprenant des sécrétomes et leurs procédés d'utilisation
WO2020180904A1 (fr) Administration de médicament pour l'association d'une modulation épigénétique et d'un blocage de point de contrôle immunitaire
WO2025171300A1 (fr) Lipides et nanoparticules lipidiques les comprenant
WO2025207803A1 (fr) Composés lipidiques, compositions et méthodes d'utilisation associées
JP7579570B2 (ja) 術後治療用ｉｎ ｓｉｔｕ噴霧生体応答性免疫療法ゲル
WO2021051066A1 (fr) Thérapie par dc1 pulsées avec her3
EP4608812A1 (fr) Lipides à base de vitamine et nanoparticules lipidiques les comprenant
EP4630562A1 (fr) Vaccin contre le cancer à base d'acide nucléique et méthodes associées
EP3873504B1 (fr) Apport d'agents thérapeutiques anticancéreux médié par des adipocytes
US20250049936A1 (en) Bioorthogonal compositions
WO2024044370A1 (fr) Compositions et méthodes d'administration d'agents actifs comprenant des acides nucléiques
WO2024206077A2 (fr) Régimes de dosage et polythérapies utilisant l'archivexine pour le traitement du cancer
CN121013733A (zh) Archexin的脂质体组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25752863

Country of ref document: EP

Kind code of ref document: A1